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ABSTRACT OF THE DISSERTATION 
Molecular Mechanisms of Programmed Necrotic Death Initiated by Intrinsic Death Signals 
by 
Gary Xiaoshi Wang 
Doctor of Philosophy in Biology & Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2014 
Professors Emily H.-Y. Cheng, Chair, and Kendall J. Blumer, Co-Chair 
 
Proper regulation of cell death is critical for tissue development and homeostasis, with 
deregulation implicated in many illnesses. Cell death is morphologically categorised as apoptosis, 
autophagy, and necrosis, with apoptosis being the best studied. BCL-2 family members are 
critical apoptosis regulators. Death signals induce upstream “activator” BH3-only molecules to 
activate the essential mitochondrion apoptosis effectors BAX and BAK to execute death. Yet, 
combined loss of Bax and Bak causes developmental and homeostatic defects in restricted 
tissues, indicating the existence of additional death program(s). By using Bax-/-Bak-/- double-
knockout (DKO) mouse embryonic fibroblasts (MEFs) to study non-apoptotic death, we 
discovered DNA double strand breaks (DSBs) activate a genetic program that upregulates 
reactive oxygen species (ROS) and the lysosomal protease cathepsin to execute a form of 
“programmed necrotic death” (PND). This refutes the long-held view that necrosis is a passive 
reponse to unmanageable physico-chemical stress. However, the PND execution pathways 
triggered by death signals and the determinants of death versus long-term survival are unclear. 
Here, I demonstrated a critical role for the transcription factor ΔNp63α in determining 
long-term survival in the face of oxidative stress, a central necrotic mediator. ΔNp63α protected 
DKO MEFs against PND and enhanced long-term survival via a novel ability to control 
intracellular redox homeostasis by regulating glutathione metabolism. ΔNp63α overexpression 
protected from oxidative stress induced by oxidants, DNA damage, and anoikis, while deficiency 
of ΔNp63α increased oxidative stress and sensitized to oxidant-induced death. I further found that 
	   x 
long-term survival of anchorage-dependent cells following loss of matrix attachment was 
enhanced by combined inhibition of apoptosis and oxidative stress by BCL-2 and ΔNp63α, 
respectively. Furthermore, I showed that in DKO MEFs, DSBs triggered an ATM-mediated DNA 
damage response that increased ROS production by upregulating the activity of complex III of the 
electron transport chain. My work concluded a key role for oxidative stress in the loss of long-term 
survival triggered by intrinsic death signals and revealed an important role for ΔNp63α in 
regulating redox homeostasis. These findings laid the groundwork for future studies on 
programmed necrotic death initiated by intrinsic death signals. 
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-CHAPTER ONE- 
 
Introduction 
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1.1 Introduction 
For metazoans, the ability of individual cells to respond correctly to pro-survival and pro-
death signals is central to embryonic development and tissue homeostasis1. Accordingly, 
dysregulated cell death contributes to the pathogenesis of many human diseases2. Insufficient 
cell death can lead to cancer and autoimmunity while execessive cell death is implicated in 
neurodegeneration and ischemic injury2. Although cell death has been recognized since the 
1800s to be a normal part of embryonic development, it was not until the latter half of the 20th 
century that fundamental insights on the regulation of cell death began to emerge3. Not 
surprisingly, these insights have opened many avenues for therapeutic intervention in a broad 
range of pathological settings4. 
Cell death is categorized into three forms based on morphological features (Fig. 1.1). The 
first form, apoptosis, has been the most extensively studied and is characterized by prominent 
nuclear condensation and fragmentation, preservation of plasma and organelle membrane 
integrity, and formation of apoptotic bodies5. It is an evolutionarily conserved, highly regulated, 
genetically encoded process that has long been synonymous with “programmed cell death”5. The 
second form is autophagic cell death, characterized by the formation of double membrane 
vesicles, i.e. autophagosomes. Autophagy is mainly a prosurvival mechanism to help cells during 
nutrient deprivation, yet exessive autophagy certainly compromises the survival of cells and leads 
to cellular demise5. The third form is necrosis, which features cytoplasmic translucency, irregular 
chromatin condensation, organellar and cellular swelling, loss of plasma and organelle membrane 
integrity, and spillage of intracellular contents into the extracellular space5, 6. 
Necrosis was traditionally thought to be an unregulated, accidental outcome of exposure 
to unmanageable physico-chemical stress7. The first clue to indicate otherwise came in 1988 
when it was reported that tumor necrosis factor (TNF) can induce either apoptosis of necrosis, 
depending on the cell type8. Accumulating evidence since then, both from our lab and many 
others, have established the existence of molecular mechanisms that control necrotic death9, 10. 
This recent emergence of “programmed necrotic death” represents a true paradigm shift in a field 
that has long equated “programmed cell death” with “apoptosis”. It is important to note that, in the 
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absence of phagocytic clearance, the morphological endpoint of all types of cell death will 
resemble necrosis due to the eventual loss of plasma membrane integrity6. This consequence of 
the gradual degradation of biological materials over time is referred to as secondary necrosis and 
is distinct from primary necrosis, which describes a cell death mechanism6.  
In both apoptosis and programmed necrosis, diverse signals ultimately converge on the 
molecular mechanisms that integrate and interpret these cues to make critical life or death 
decisions for the cell1, 10. In the case of apoptosis, execution of cell death is mediated by 
caspases, a family of cysteine proteases activated by extrinsic or intrinsic death signals1. 
Caspase activation results in the stereotypical biochemical and morphological hallmarks of 
apoptosis; therefore, caspase-dependent cell death is synonymous to apoptosis5. Although the 
pathways that initiate and execute programmed necrosis have not been as extensively elucidated 
as the ones that control apoptosis, clear themes have emerged. Similar to apoptosis, both death 
receptor ligation and intrinsic death signals can trigger programmed necrosis10. However, unlike 
apoptosis, the execution of programmed necrosis does not rely on caspases10. Rather, evidence 
suggest it involves a complex interplay of reactive oxygen species (ROS), organelle dysfunction, 
and dysregulated intracellular calcium homeostasis10. The mitochondria and lysosomes have 
emerged as the target organelles within this network of effectors7. The aim of this thesis is to 
further our understanding of the molecular mechanisms that govern programmed necrotic death 
in response to intrinsic death signals. 
 
1.2 Apoptosis 
Introduction 
Though there are reports going as far back as the 1800s describing cells that appeared 
to die as a normal part of development, cell death was not established to be a normal biological 
process until Alfred Glucksmann’s comprehensive 1951 review3. In that article, he summarized 
and categorized instances of cell death observed during vertebrate development and stated that 
these cells shared a set of morphological characteristics that we now recognize as apoptotic3. 
Then in 1965, Richard Lockshin and Carroll Williams, in a report on the death of larval muscles of 
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metamorphosing insects, introduced the term “programmed cell death” to describe this form of 
death that appeared to be triggered in otherwise healthy cells by a specific series of physiological 
events versus death elicited by toxic or inhospital environments11. In that same year, the 
pathologist John Kerr proposed the term “shrinkage necrosis” to describe the process that 
resulted in the appearance of small, condensed, acidophilic, enucleated cytoplasm in the liver 
under pathological conditions12. Then, in a landmark 1972 study, Kerr and colleagues changed 
that term to “apoptosis” to clearly distinguish it from necrosis and to highlight its presumed 
importance in the regulation of tissue cell number under both physiological and pathological 
conditions13. In that study, apoptosis was described to occur in two discrete, sequential stages. 
The first stage is marked by condensation of the nucleus and cytoplasm, nuclear fragmentation, 
and breaking up of the cell into numerous membrane-bound, well-preserved cell remnants i.e. 
apoptotic bodies. In the second stage, apoptotic cells are ingested by neighboring cells and 
degraded within phagosomes. Histologically, apoptosis was observed to result in minimal tissue 
disruption with no evidence of inflammation. Based on previous findings in developmental biology 
and the histological and ultrastructural features of apoptosis, the authors believed apoptosis to be 
the regulated process responsible for counterbalancing cell proliferation to ensure normal 
development and tissue homeostasis. 
 
Genetic control of programmed cell death in Caenorhabditis elegans 
 Based on the observation that a wide variety of simuli were able to initiate the 
stereotyped events of apoptosis, Kerr and colleagues suggested that “apoptosis [may depend] on 
the expression of part of the genome, which is normally repressed in viable cells”13. A series of 
studies performed using the nematode Caenorhabditis elegans by Sydney Brenner, John 
Sulston, and H. Robert Horvitz established that programmed cell death in the worm is indeed a 
genetically regulated process14. Cell lineage tracings performed by Brenner and Sulston using the 
C. elegans hermaphrodite demonstrated that over the course its development, the same 131 cells 
out of the initial 1090 always died. Subsequent mutagenesis studies carried out by Horvitz and 
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colleagues identified the genes that constitute the core pathway governing programmed cell 
death in C. elegans. 
 The first three cell death genes identified in C. elegans were nuc-1, ced-1, and ced-2. 
Nuc-1 was discovered by Sulston when he observed that in one particular mutant, densely-
staining masses of DNA were found at the locations of cells that normally undergo programmed 
cell death14. He discovered that the gene defined by this mutant encoded a DNA endonuclease 
responsible for DNA degradation during cell death. Ced-1 and ced-2 were then identified as two 
genes responsible for the phagocytosis of dead cells15. In these mutants, the death process is 
initiated but the cell remants persist due to defective clearance from the surrounding tissue, 
allowing the cell corpses to be readily visualized in living animals15. Horvitz and colleagues 
carried out subsequent mutagenesis screens of programmed cell death regulators on a ced-1 
mutant background to exploit the persistence of dead cells in this mutant and identified a mutant 
in which no cell corpses could be found 16. The gene defined by this mutation is ced-316, later 
cloned and found to be a cysteine protease homologous to a mammalian protease, the 
interleukin-1β converting enzyme (ICE) or caspase-117. Subsequent screens uncovered the rest 
of the core C. elegans cell death regulatory pathways: the pro-death genes egl-118 and ced-416, 
and the anti-death gene ced-919. In response to death signals, Egl-1 is transcriptionally 
upregulated and undergoes mitochondrial translocation, where it displaces CED-4 from its 
inhibitor CED-920. Once released from CED-9, CED-4 translocates to the perinuclear region, 
oligomerizes, and interacts with CED-3 to promote its autocatalytic activation1, 21. For their work, 
Brenner, Sulston, and Horvitz were honored with the 2002 Nobel Prize in Physiology or Medicine. 
 
Mammalian apoptosis: caspases 
As in C. elegans, the execution of apoptosis in mammalian cells likewise depends on the 
activity of a family of proteases. The mammalian CED-3 homologue ICE, or caspase-1, is the 
founding member of this family of proteases that use a cysteine nucleophile to catalyze peptide 
bond hydrolysis in motifs bearing aspartic acid22. Thus they are named caspases, a contraction of 
cysteine-dependent aspartate-specific protease. Synthesized as catalytically inactive zymogens, 
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caspases possess an N-terminal prodomain followed by a large and small subunit22. The human 
genome encodes 11 caspases, traditionally split into two major subgroups based sequence 
homology and function23. The first group are “inflammatory” caspases, which are primarily 
activated in cells of the innate immune system to regulate inflammation through the processing of 
cytokines 23. The second group consist of “apoptotic” caspases, activated during apoptosis and 
responsible for the execution of the death program23. The apoptotic caspases are further 
subdivided into upstream initiator caspases that are activated by adaptor-induced proximity and 
downstream effector caspases that are cleaved and activated by initiator caspases24. Initiator 
caspases possess a long prodomain that mediates interactions with their adaptor proteins while 
effector caspases possess a short prodomain24. There are two varieties of initiator caspase 
prodomains: the caspase-recruitment domain (CARD) and the death-effector domain (DED)24. 
 Activation of inactive monomeric initiator caspases requires homodimerization mediated 
by their recruitment to activation complexes formed following an apoptotic signal25. According to 
the induced proximity model, homotypic interactions between the caspase prodomain and 
adaptor proteins in these complexes activate caspases via an enforced increase in local caspase 
concentration25. Three mammalian apoptotic initiator caspase activation complexes have been 
identified: the apoptosome, the death-inducing signalling complex (DISC), and the PIDDosome26. 
The apoptosome describes a complex of cytochrome c, APAF-1 (apoptotic protease activating 
factor-1), and caspase-927. The APAF-1 CARD domain, which mediates interaction with caspase-
9, is normally bound by two C-terminal WD40 domains and thus unable to bind with the 
caspase28. Upstream death signals that culminate in the permeabilization of the mitochondrial 
outer membrane (MOM) release cytochrome c, which binds to APAF-1 through its WD40 
domains, making its CARD domain available to recruit caspase-928. Inactive APAF-1 also binds 
one molecule of ADP/dADP via its nucleotide binding domain28. Conformational changes in 
APAF-1 due to interaction with cytochrome c allows ADP/dADP to be exchanged for ATP/dATP, 
the hydrolysis of which induces a conformational change that permits its oligomerization into the 
heptameric apoptosome29, 30. The prototypical DISC is formed following ligation of the Fas death 
receptor31. Fas, which is preassembled in the plasma membrane as a trimer32, undergoes a 
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conformational change mediated by weak protein-protein interactions resulting from ligand-
induced receptor clustering, leading to the assembly of the adaptor protein FADD to its 
cytoplasmic tail, which in turn recruits caspase-8 via the DED33. This results in high local 
concentrations of caspase-8, leading to its proximity-induced activation25. Finally, the PIDDosome 
is the caspase-2 activating complex composed of caspase-2, the adaptor protein RAIDD, and 
PIDD, in which proteolytically activated PIDD recruits RAIDD and caspase-2 leading to its 
activation34. 
 Effector caspases exist as inactive dimers that are activated following proteolytic 
cleavage between their large and small subunits by initiator caspases and by the lymphocyte-
specific serine protease granzyme B22. Structural studies on caspase-7, a representative effector 
caspase, demonstrates the mechanistic basis for proteolytic activation35, 36. Following cleavage, 
the core structural elements of caspase-7 remain unchanged and the protease remains as a 
homodimer. However, drastic conformational changes of active site loops shift the active site from 
a closed state to an open one capable of binding substrate. Once active, effector caspases go on 
to cleave their intracellular targets to execute apoptosis. A large number of proteins have been 
reported to be in vivo caspase substrates, with targeted proteomics approaches revealing that 
over 200-300 cellular proteins are cleaved in a caspase-dependent manner following induction of 
apoptosis37, 38. Of note, the organized degradation of nuclear DNA into 180 bp internucleosomal 
fragments, one of the key hallmarks of apoptosis, is mediated by the DNase CAD39. In the 
absence of apoptotic signals, CAD is sequestered in the cytoplasm by its inhibitor ICAD39. Once 
activated either via the DISC or the apoptosome, effector caspase-3 cleaves ICAD, releasing 
CAD to translocate into the nucleus to degrade chromosomal DNA40. 
 Besides regulating its activation, cells also possess additional regulatory mechanisms to 
prevent unwanted, potentially lethal caspase activity25. First, caspase inhibition is exemplified by 
the human caspase inhibitor XIAP, the most extensively studied member of the inhibitor of 
apoptosis (IAP) protein family41. This multidomain protein achieves selective tight inhibition of 
both initiator (caspase-9) and effector (caspase-3 and -7) caspases via utilizing a two-site 
mechanism41. Caspase inhibition is also mediated by decoy proteins that structurally mimic 
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caspase prodomains to compete for the same adaptors in activation platforms. For example, 
FLIP, a caspase-8 mimic with a nonfunctional catalytic domain, prevents caspase-8 recruitment 
to the DISC42, 43. Finally, inhibition of caspase activity can be achieved via proteosomal 
degradation, with cellular IAPs, which contain domains involved in ubiquitin ligation, proposed to 
mediate proteosomal removal of caspases25, 44, 45. 
 
Intrinsic and extrinsic mammalian apoptosis pathways 
In mammals, apoptosis can be initiated via either the intrinsic or the extrinsic pathway1. 
The intrinsic pathway is activated by a wide range of stimuli including DNA damage, ER stress, 
and cytokine/growth factor depletion1. Upstream pro-survival and pro-death signals are 
transduced and integrated by the BCL-2 family of proteins, which controls apoptosis by regulating 
mitochondrial outer membrane (MOM) integrity1. MOM permeabilization, generally considered to 
irreversibly commit the cell to death following intrinsic death stimuli, leads to the release of 
cytochrome c46 as well as other apoptogenic molecules such as Endo G47, Smac/DIABLO48, 49, 
and HtrA2/OMI50, and from the intermembrane space (IMS). 
The extrinsic pathway is triggered by the ligation of cell surface death domain-containing 
receptors such as Fas, TNFR1, and DR4/51. Receptor ligation leads to the formation of the DISC 
and caspase activation, as described in the previous section. Depending on whether or not MOM 
permeabilization is required for the DISC to induce effector caspase activation and cell death, 
cells can be divided into two types51. Type I cells, typified by T lymphocytes, do not require MOM 
permeabilization and cytochrome c release for effector caspase activation, and therefore are not 
protected by inhibition of MOM permeabilization by overexpression of anti-apoptotic BCL-2 family 
members BCL-2 or BCL-XL51. In those cells, a large amount of caspase-8 is recruited to and 
activated at the DISC, leading to effector caspase activation. In contrast, Type II cells, typified by 
hepatocytes, have lower levels of caspase-8 and higher levels of XIAP compared to Type I cells, 
thus abrogating the ability of caspase-8 to directly activate effector caspases51, 52. In these cells, 
activation of effector caspases requires amplification of the death signal by the mitochondrial 
apoptosis pathway53, 54. In this scenario, proteolytic activation of BID to truncated BID (tBID) by 
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caspase-8 results in MOM permeabilization, releasing cytochrome c and Smac/DIABLO, which 
respectively induces apoptosome formation and neutralizes XIAP, thus leading to effector 
caspase activation52-55. Importantly, the level of XIAP expression has been shown to be a critical 
determinant of whether a cell is Type I versus Type II52. In that study, hepatocytes in the liver of 
Bid-/- mice, which do not engage the mitochondrial pathway downstream of DISC and are thus 
resistant to apoptosis induced by injection of FasL56, were rendered sensitive by combined loss of 
both Bid and XIAP52. 
 
The BCL-2 family 
  The identification of the BCL-2 (B-cell lymphoma 2) proto-oncogene at the chromosomal 
breakpoint of t(14;18) in human follicular B-cell lymphoma resulted not only in the establishment 
of the BCL-2 family of proteins, which constitute a critical intracellular checkpoint in intrinsic 
apoptosis, but also created a new paradigm in cancer biology1. All oncogenes discovered prior to 
BCL-2 promoted tumorigenesis by increasing cell growth and proliferation. However, the t(14;18) 
translocation, in which the immunoglobulin heavy chain promoter and enhancer drive BCL-2 
overexpression, did not increase proliferation but rather rendered cells resistant to apoptosis57. 
The oncogenic potential of BCL-2 was demonstrated by Stanley J. Korsmeyer and colleagues in 
two landmark studies published in 1989 and 1991 using the BCL-2-Ig transgenic mice, which 
carry a minigene that structurally mimics the t(14;18)58,59. In humans, follicular lymphoma is often 
an indolent disease comprised of small resting B cells that frequently progresses to high-grade 
lymphoma. Similarly, in the 1989 study, the investigators reported that BCL-2-Ig mice developed 
polyclonal follicular hyperplasia of resting B cells. In that study, the investigators also reported the 
important observation that the BCL-2-Ig transgene endowed mature B cells with a prominent 
survival advantage when grown in vitro in simple liquid culture. In their subsequent 1991 study, 
the investigators reported that in the BCL-2-Ig mice, B cell polyclonal follicular hyperplasia 
progressed to high-grade monoclonal lymphoma following a long latency period, reflecting the 
clinical couse of human follicular lymphoma. The latency period preceding the appearance of 
monoclonal disease indicated to the investigators that secondary changes were responsible for 
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the progression from hyperplasia to lymphoma. Indeed, half of the high-grade lymphomas 
harbored rearrangement of c-Myc, a proto-oncogene that drives cell growth and proliferation, and 
which had been shown to synergize with BCL-2 in vitro. In summarizing their findings, the authors 
proposed BCL-2 to be the founding member of a novel category of proto-oncogenes that drive 
tumorigenesis not by promoting growth and proliferation, but rather by functioning “as an antidote 
against death”. And indeed, the evasion of cell death has been proven to be a hallmark of cancer 
progression60. 
The BCL-2 family contains approximately 20 proteins and is divided into three subfamilies 
based on their death regulatory activity and homology shared within four conserved BCL-2 
homology domains (BH1-4)61. The anti-apoptotic members include BCL-2, BCL-XL, and MCL-1. 
Pro-apoptotics are further divided into multidomain members BAX and BAK, and a diverse group 
of BH3-only members. Studies from our lab have further defined two groups of BH3-only 
molecules: ones that directly activate BAX/BAK and ones that indirectly activate BAX/BAK 
through inactivating BCL-2/BCL-XL/MCL-162. Upon apoptosis, the “activator” BH3-only molecules 
(BH3s), including tBID, BIM, and PUMA, trigger homo-oligomerization of BAX and BAK to 
mediate cytochrome c efflux, leading to caspase activation. Conversely, the anti-apoptotic BCL-
2/BCL-XL/MCL-1 sequester activator BH3s into inert complexes, thus preventing the activation of 
BAX/BAK. The remaining BH3s including BAD, NOXA, BMF, HRK, and BIK/BLK do not activate 
BAX and BAK directly, but instead prevent the anti-apoptotic BCL-2 members from sequestering 
the activator BH3s. Thus, the inactivator BH3s can displace activator BH3s from anti-apoptotics 
to activate BAX and BAK indirectly. The data from this study established a hierarchical regulation 
of mitochondrion-dependent apoptosis by BCL-2 subfamilies (Fig. 1.2). In the absence of death 
stimuli, BAX and BAK are both inactive monomers, with BAX in the cytosol and BAK in the 
mitochondrial outer membrane (MOM)61. Mitochondrial BAK is kept in an inactive conformation 
through its association with the MOM protein VDAC263. Once activated, BAX inserts into the 
MOM as homo-oligomers while BAK also homo-oligomerizes, leading to MOM permeabilization, 
release of cytochrome c from the intermembrane space (IMS), and apoptosome formation61, 64. 
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Targeted gene deletion has demonstrated that BAX and BAK constitute the essential 
gateway to mitochondrial apoptosis65. Unlike the stable and ubiquitously-expressed BAX and 
BAK, a third pro-apoptotic multidomain BCL-2 family member, BOK, is labile with prominent 
expression restricted to the reproductive organs and is therefore not essential for cytochrome c 
release66. The functional redundancy of BAX and BAK is apparent when comparing the mild 
phenotypes of Bax-/- mice and Bak-/- mice with the severe phenotype of mice deficient for both 
Bax and Bak67. Bak-/- mice have no overt phenotype while the Bax-/- mice displays mild lymphoid 
hyperplasia and male sterility due to defective sperm-cell differentiation. However, most Bax-/-Bak-
/- mice die perinatally with fewer than 10% surviving to adulthood. The exact cause of perinatal 
lethality of the Bax-/-Bak-/- mice is still unknown. The surviving mice demonstrated developmental 
defects including persistence of interdigital webs, an imperforate vaginal canal, and accumulation 
of excess cells in the central nervous and hematopoietic systems. Importantly, the elimination of 
interdigital webs during the formation of digits in higher vertebrates via programmed cell death is 
a well-described example of its role in tissue remodeling68 and was completely rescued by just 
one wild-type Bax or Bak allele. Furthermore, neither intrinsic death signals nor overexpression of 
BH3-only molecules were able to induce cytochrome c release and apoptotic death in cells 
deficient for both Bax and Bak65, 69, 70. 
The nature of the cytochrome c-releasing pore formed by the BAX and BAK homo-
oligomeric complexes on the MOM is still under investigation. Much more is known about the 
molecular mechanisms governing BAX and BAK activation, a tightly regulated process mediated 
by dynamic interactions with activator BH3-only molecules. For both BAX and BAK, activation 
means that these normally inactive, monomeric proteins undergo conformation changes and 
homo- oligomerization61, 71. While BAK always resides in the MOM, BAX is mostly cytosolic with a 
small fraction loosely associated with the mitochondria61, 64. Therefore, unlike BAK, BAX 
activation requires the additional step of mitochondrial translocation. The insertion of BAX and 
BAK into the MOM is mediated by its C-terminal α9 helix61, 72. Our lab found that for BAX, in the 
absence of death signals, the N-terminal α1 helix stabilizes the α9 in the dimerization pocket 
formed by the BH1-3 domains, thus preventing BAX mitochondrial targeting64. In the presence of 
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upstream death signals, activator BH3-only molecules tBID, BIM, and PUMA transiently bind the 
α1 helix to drive N- and C-terminal exposure, thereby freeing the α9 helix for MOM insertion. 
tBID, BIM, and PUMA then drive the homo-oligomerization of mitochondrially-localized BAX. The 
α1 helix of BAK is always exposed, thus allowing it to be constitutively targeted to the MOM 
where it is kept inactive through binding with the MOM protein VDAC2 via its dimerization pocket. 
Death signals induce activator BH3-only molecules to disrupt the inhibitory BAK-VDAC2 
interaction to enable BAK homo-oligomerization. The essential role of the activator BH3-only 
molecules in directly activating BAX and BAK was clearly demonstrated by our studies on 
knockout mice deficient for Bid, Bim, and PUMA73. The Bid-/-Bim-/-PUMA-/- mice displayed the 
same developmental defects associated with Bax-/-Bak-/- mice, including interdigital webbing and 
imperforate vaginas. Furthermore, despite the presence of other BH3-only molecules, combined 
deficiency of Bid, Bim, and PUMA prevented BAX and BAK homo-oligomerization, cytochrome c 
release, and caspase activation in response to intrinsic death signals in neurons and T 
lymphocytes. 
 
Regulation of the BCL-2 family by life and death signals 
 Given its central role in the regulation of apoptosis, the BCL-2 family is understandably 
under tight control by both pro-death and pro-survival signals at the transcriptional and post-
transcriptional level61. The ratio between pro- and antiapoptotic BCL-2 family members 
constitutes a rheostat that sets the threshold of susceptibility to apoptosis1. Pro-death signals shift 
the ratio to favor BAX/BAK activation while pro-survival signals do the opposite. For example, 
following death receptor ligation and DISC formation, inactive cytosolic BID is proteolytically 
converted by caspase-8 to the active, mitochondrially targeted tBID53, 54. Cleavage of BID by 
caspase-8 results in its N-myristoylation via a newly-exposed glycine, thus driving its 
translocation to the MOM. Additionally, genotoxic stress upregulates the pro-apoptotic BH3-only 
molecules NOXA and PUMA via the transcription factor p5374-76. Endoplasmic reticulum (ER) 
stress activates the transcription of BIM via the transcription factor CHOP and induces 
dephosphorylation of BIM through PP2A, which prevents its ubiquitination and proteasomal 
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degradation77. Furthermore, in lymphocytes, cytokine withdrawal and subsequent shutdown of the 
pro-survival PI3K/AKT pathway leads to BIM induction via activation of the transcription factor 
FOXO3A78. On the other hand, in the presence of growth factors, BIM phosphorylation by ERK1/2 
disrupts its ability to bind BAX79. ERK1/2 phosphorylation of human BIM at Ser69 also promotes 
its subsequent phosphorylation by Rsk1/2, which mediates its binding to the E3 ligase SCFβTrCP 
leading to its ubiquitination and proteasomal degradation80. 
Antiapoptotic BCL-2 family members are similarly regulated both transcriptionally and 
post-transcriptionally by pro-death and pro-survival signals. BCL-XL is transcriptionally induced via 
the JAK-STAT pathway following the activation of cytokine receptors81. Furthermore, upregulation 
of BCL-XL by the transcription factor NF-kB mediates the pro-survival effects of CD28 co-
stimulation during T cell receptor (TCR) activation in T lymphocytes82, 83 and of CD40 activation in 
B lymphocytes84. Post-transcriptional regulation of antiapoptotic BCL-2 family members is 
exemplified by MCL-1. Due to the presence of a PEST region upstream of its BH3 domain, MCL-
1 protein is more labile than BCL-2 and BCL-XL and is rapidly downregulated during apoptosis, 
suggesting it is important in rapidly shifting the threshold of susceptibility to apoptosis in response 
to acute environmental changes85. Upon DNA damage, the HECT-domain-containing E3 ubiquitin 
ligase MULE ubiquitinates MCL-1, leading to its proteosomal degradation86. Furthermore, DNA 
damage and cytokine withdrawal result in phosphorylation of MCL-1 by the kinase GSK-387. 
Phosphorylated MCL-1 is then ubiquitinated and targeted to the proteosome by the E3 ligase 
SCFβTrCP. GSK-mediated MCL-1 phosphorylation also targets it for polyubiquitination and 
degradation by the tumor suppressor E3 ubiquitin ligase SCFFBW7, indicating that the loss of 
FBW7 observed in diverse human cancers may contribute the tumorigenesis through 
upregulation of MCL-1 expression88. Finally, during mitotic arrest induced by antitubulin 
chemotherapeutic agents, MCL-1 is phosphorylated by GSK-3 and subsequently ubiquitinated 
and targeted for proteasomal degradation by the tumor suppressor E3 ubiquitin ligase SCFFBW7 89. 
In contrast, stabilization of MCL-1 and consequent promotion of cell survival is mediated by the 
deubiquitinase USP9X, which directly interacts with and deubiquitinates MCL-190. Interestingly, 
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the same study demonstrated that expression levels of MCL-1, which is known to be abnormally 
high in a range of human cancers, directly correlates with USP9X expression in human tumors. 
 
Caspase-independent cell death 
Even in the absence of caspase activation, the induction of BAX and BAK homo-
oligomerization by activator BH3-only molecules has lethal consequences for the cell due to 
mitochondrial dysfunction69, 91. Indeed, mitochondrial outer membrane permeabilization (MOMP) 
is generally considered to be the “point of no return” commiting a cell to death regardless of 
caspase activation. The occurrence of caspase-independent cell death (CICD) in vivo is apparent 
upon comparing the phenotype of Apaf-1-/- 92 and Caspase-9-/- 93 mice with that of Bax-/-Bak-/- 67 
and Bid-/-Bim-/-Puma-/- 73 mice. The elimination of interdigital webs was only delayed by 2 days in 
Apaf-1-/- mice92 and occurred normally in Caspase-9-/- mice93. However, interdigital webs 
persisted into adulthood in both Bax-/-Bak-/- and Bid-/-Bim-/-Puma-/- mice. The accumulation of 
neuronal cells observed in adult Bax-/-Bak-/- mice was likewise absent in adult mice deficient in 
Apaf-1 or Caspase-9. Furthermore, deficiency in Apaf-1, Caspase-9, or Caspase-3 provides only 
transient protection against death induced by BH3-only molecules despite the lack of caspase 
activation while Bax-/-Bak-/- cells were completely protected69. 
In healthy cells, the mitochondrial inner membrane (MIM), which separates the matrix 
from the intermembrane space (IMS), is highly impermeable to water and ions while the 
mitochondrial outer membrane (MOM) is generally assumed to be freely permeable to small 
metabolites and solutes up to ~5 kDa91. The impermeability of the MIM allows the embedded 
electron transport chain (ETC) to generate a proton gradient across the membrane, which forms 
the basis of the inner mitochondrial transmembrane potential (ΔΨm)94. This electrochemical 
gradient is positively charged and acidic on the side facing the IMS and negatively charged and 
alkaline on the matrix-facing side. The proton gradient is used by the ATP synthase enzyme 
complex, located in the MIM, to generate ATP from ADP and is also used by ion-exhange 
channels to regulate mitochondrial ion homeostasis. The ΔΨm set up by the proton gradient is 
also required for protein import into the mitochondrial matrix since it both activates the inner 
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membrane protein import channel and drives positively charged presequences into the matrix. 
Accordingly, the loss of ΔΨm that occurs following MOMP leads to loss of ATP production, ion 
homeostasis, and mitochondrial protein import91. Mitochondrial dysfunction induced by BAX/BAK 
activation can be caspase dependent or independent. Caspase-3 can cleave the p75 subunit of 
the complex I of the electron transport chain, leading to loss of ΔΨm95. The molecular 
mechanisms underlying caspase-independent mitochondrial dysfunction are still unclear. 
Although release of cytochrome c, a component of the ETC, may be expected to inhibit ETC 
activity thus leading to loss of ΔΨm, there is evidence that the concentration of cytochrome c in 
the IMS following MOMP is sufficient for ETC function96. ΔΨm has also been suggested to result 
from inactivation of ETC enzymes by cytosolic enzymes that are activated and/or gain entry to the 
IMS following MOMP. In support of this, one study showed the caspase-independent loss of 
activity of ETC complexes I and IV following MOMP97. Mitochondrial protein import is also actively 
shut down following MOMP due to degradation of TIM23, an essential component of the inner 
membrane protein import machinery, leading to a loss of cell viability98. 
The release of IMS proteins AIF, Endo G, and HtrA2/Omi following MOMP has also been 
implicated in CICD91. AIF is a phylogenetically conserved flavoprotein with NADH oxidase activity 
shown to be involved in the assembly and maintenance of Complex I of the ETC99. Following 
MOMP, AIF translocates into the nucleus and mediates chromatin condensation and large-scale 
DNA fragmentation100. Loss of AIF also impairs oxidative phosphorylation due to a decrease in 
ETC complex I activity99. Likewise, Endo G, the predominant mitochondrial endonuclease 
proposed to mediate mitochondrial biogenesis and DNA synthesis and repair, also translocates to 
the nucleus following MOMP where it has been shown to degrade chromatin47. HtrA2/Omi is a 
serine protease that can both mediate caspase-dependent cell death via inhibitory interactions 
with IAPs and through caspase-independent mechanisms that depend on it proteolytic activity50. 
Evidence indicate that loss of HtrA2/Omi is also deleterious to the mitochondria101, 102. Under 
normal circumstances, HtrA2/Omi is proposed to mediate protein quality control in the IMS by 
degrading denatured proteins. Mice bearing homozygous deletion of HtrA2/Omi or a point 
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mutation that disrupts its protease activity die prematurely and exhibit neurodegeneration, 
possibly due to mitochondrial dysfunction. 
 
1.3 Autophagy 
Macroautophagy, referred to from here on out as autophagy, is an evolutionarily 
conserved process in eukaryotes by which proteins, organelles, and cytoplasmic content are 
sequestered by double-membrane vesicles, termed autophagosomes, and delivered to 
lysosomes for degradation103. Basal, constitutive autophagy maintains cellular homeostasis by 
mediating the elimination and recycling of old or damaged organelles as well as turnover of long-
lived proteins and protein aggregates103. Autophagy is also a survival response stimulated by 
multiple forms of cellular stress such as nutrient depletion, hypoxia, damaged organelles, and 
pathogen invasion104. One of the most important roles for autophagy is to provide energy for vital 
cellular functions via digestion of the cell’s own contents104. Autophagic cell death (ACD) is 
morphologically defined as cell death accompanied by prominent vacuolization of the cytoplasm 
due to large-scale autophagosome formation5. Although the bulk of the evidence indicates that 
autophagy primarily promotes cell survival, it is conceivable that excessive autophagy can 
ultimately lead to cellular demise. However, it remains unclear whether there are regulatory 
mechanisms that specifically activate autophagy to execute cell death. 
 
Core mammalian autophagy machinery 
Although the molecular control of autophagy was initially investigated in yeast, the 
process of autophagy is largely conserved between yeast and mammals103. Figure 1.3 depicts a 
simplified schematic of mammalian autophagosome formation. The first step of mammalian 
autophagy is autophagosome nucleation, in which a small, flat, crescent-shaped organelle termed 
the phagophore or isolation membrane is nucleated by core components of the autophagosome 
machinery. The isolation membrane then elongates and expands around cytoplasmic contents 
until a double-membraned autophagosome is formed upon complete envelopment of a portion of 
the cytoplasm or damaged organelles. Studies have shown that membrane components required 
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to form the autophagosome membrane can originate from the mitochondria outer membrane105  
and the endoplasmic reticulum106. The autophagosome then fuses with the lysosome to form the 
autophagosome, where the inner membrane of the autophagosome and its cargo of cytoplasm-
derived material are then degraded by lysosomal hydrolases. Monomeric units such as amino 
acids generated by the degradation of macromolecules are then exported to the cytosol for reuse 
through permeases that are still poorly characterized. At the peak of autophagy a large 
percentage of lysosomes may be subsumed into autophagosomes and that, upon cessation of 
autophagy, proto-lysosomal membrane components are recycled via tubules and vesicles to form 
new lysosomes107. 
The mechanism of autophagosome formation requires a highly orchestrated, 
evolutionarily-conserved series of events that are still being elucidated. Nutrient depletion is the 
most typical and potent inducer of autophagy104. Briefly, the unc-51-like kinase (ULK) complexes 
are apical inducers of autophagosome formation that, upon nutrient depletion, are activated and 
localize at the phagophore108, 109. Nucleation, and also subsequent maturation of the 
autophagosome, requires the VPS34 class III phosphatidylinositol-3 kinase (PI3K)-Beclin 1 
complexes110-113. Beclin 1 plays an important role in tumorigenesis that will be discussed in more 
detail in a later section110. The PI3K complex generates phosphatidylinositol 3-phosphate 
(PtdIns(3)P) in the phagophore membrane, an event required for recruitment of other 
components of the autophagy machinery103. Phagophore elongation and closure requires the 
Atg12 and Atg8/LC3 ubiquitin-like protein conjugation systems103, 114. Atg12 is conjugated to Atg5 
in a reaction mediated by the E1-like enzyme Atg7 and the E2-like enzyme Atg10, which then 
interacts with Atg16 to form the large multimeric Atg16L complex on the cytoplasmic side of the 
phagophore membrane103. C-terminal cleavage of Atg8/LC3 by Atg4 generates LC3-I, which is 
conjugated to phosphatidylethanolamine (PE) to generate LC3-II on the phagophore membrane 
in an Atg7- and Atg3-dependent manner where it mediates membrane tethering and 
hemifusion103,114. The transmembrane protein Atg9 shuttles between the phagophore and 
peripheral sites to presumably deliver membranes to the developing phagophore, and does so in 
an ULK- and class III PI3K-dependent manner115. VMP1, another transmembrane autophagy 
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protein, is required for autophagy induced by nutrient depletion, a function that depends on its 
interaction with Beclin 1116. This sugests VMP1 may recruit class III PI3K-Beclin 1 complexes to 
the phagophore. Upon completion, the proteins that mediate autophagosome formation are 
released back to the cytoplasm through an unknown mechanism. 
 
Autophagy as part of the cellular stress response 
Autophagy is activated by diverse stresses including nutrient depletion, ER stress, and 
microbial infection or exposure to microbial products104. Of these, nutrient depletion is the most 
typical, best characterized, and most potent trigger of autophagy, which can be induced by lack of 
any essential nutrient117. Thus, while autophagy is most potently induced in yeast by nitrogen 
starvation, the withdrawal of carbon, auxotrophic amino acids and nucleic acids, and sulfate can 
all initiate autophagy117. Cultured mammalian cells similarly induce autophagy upon withdrawal of 
amino acids and glucose117. For metazoans, though, it is important to note that autophagy is not 
simply the response of an individual cell to nutrient depletion, but is also a crucial part of an 
organism’s response to starvation117,118. Therefore, autophagy is also controlled by extracellular 
growth factors and by the hormones insulin and glucagon117, 118. Indeed, one of the earliest 
observations of autophagy, made in 1962 prior even to the coining of the word, was in the 
hepatocytes of rats that had been exposed to glucagon, a hormone induced during times of 
fasting119. Insulin, which is induced during and immediately following a meal, was later shown to 
inhibit autophagy119. One of the most striking demonstrations of the importance of autophagy at 
the organismal level is the phenotype of mice deficient for the genes Atg5120 or Atg7121, which are 
essential for autophagosome formation. Although developmentally normal, they have a mortality 
rate of >90% within the first 24 period following delivery likely due to an inability to use autophagy 
to bridge over the starvation period between cessation of trans-placental nutrient supply and 
onset of suckling. One of the main purposes of autophagy during starvation is to maintain both 
intracellular and extracellular amino acid levels, both of which decrease in autophagy-deficient 
mice subjected to starvation120. The amino acids thus produced may help organisms survive 
starvation by driving hepatic gluconeogenesis, in which lactate and amino acids from peripheral 
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tissues are used by the liver via the glucose-alanine cycle to produce glucose to compensate for 
depletion of glycogen stores during prolonged starvation117. Furthermore, amino acids can also 
be used to produce oxidizable substrates for energy production via the tricarboxylic acid (TCA) 
cycle117. 
The mTOR pathway is the best-characterized regulator of starvation-induced 
autophagy104. mTOR is a serine/threonine kinase and as a component of mTOR complex 1 
(mTORC1) is central in growth factor signalling and nutrient- and energy-sensing pathways104. Its 
activation increases protein synthesis and overall cell growth when metabolic conditions are 
favorable and/or when stimulated by growth factors104. In mammalian cells, the first clue that 
mTOR suppresses autophagy was the observation that the mTOR inhibitor rapamycin induces 
autophagy in isolated rat hepatocytes122. Though the mechanism by which mTOR regulates 
autophagy is still an active area of investigation, mTOR-mediated inhibition of the ULK complex is 
central to this process103, 108. 
Sirtuins, NAD-dependent deacetylases that sense environmental stress, have also been 
implicated to play a crucial role in starvation-induced autophagy104. Evidence indicates central 
roles for sirtuins in regulating metabolism and aging-related physiological changes, and that the 
mammalian sirtuin SIRT1 mediates the lifespan-extending effects of calorie restriction123. 
Overexpression of SIRT1 was found capable of inducing autophagy while genetic deletion of Sirt1 
impaired autophagy activation in mouse embryonic fibroblasts124. In that study, SIRT1 was 
demonstrated to regulate the acetylation status of the core autophagy regulators Atg5, Atg7, and 
LC3. Furthermore, decreased association between the sirtuin SIRT2 and the transcription factor 
FoxO1 following serum starvation in human cancer cell lines leads to FoxO1 acetylation125. 
Acetylated FoxO1 in the cytosol then binds with Atg7 to promote autophagosome formation. 
 
Autophagy as a cellular housekeeper 
Autophagy is not only induced as part of a cell’s integrated response to stress, but also 
functions at a basal level as a “cellular housekeeper” that eliminates defective proteins and 
organelles and prevents the accumulation of abnormal protein aggregates103. These 
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“housekeeping” functions are viewed as central to the protective role of autophagy observed in 
neurodegenerative diseases and cancer126. Mice bearing tissue-specific deletions of Atg5 and 
Atg7 demonstrate an accumulation of protein aggregates in inclusion bodies associated with 
cellular degeneration in post-mitotic hepatocytes, cardiomyocytes, and neurons126. Additionally, 
Atg7-deficient mouse hepatocytes accumulate peroxisomes, damage mitochondria, and aberrant 
membranous structures contiguous with the ER121, 127. Since mitochondrial damage can lead to its 
overproduction of reactive oxygen species (ROS), some of the pro-survival effects of mitophagy 
have been attributed to the removal of this potential source of oxidative damage126. Similarly, 
peroxisomes generate ROS through their metabolic functions, necessitating turnover of the 
organelle due to oxidative damage of its constituents128. 
A key feature of many neurodegenerative diseases is the formation of intracellular 
aggregates129. These include Parkinson’s disease, polyglutamine expansion diseases such as 
Huntington’s disease, and forms of dementia. Early observations of autophagosomes in these 
disease settings suggested involvement of autophagy in disease pathogenesis. However, model 
organisms have shown that autophagosome formation is either part of a protective response or, 
in the case of Alzheimer’s disease, a consequence of impaired autophagosome maturation126. 
For example, mutations of the dynein motor machinery found in human neurodegenerative motor 
neuron diseases were found to reduce the clearance of aggregate-prone proteins and enhance 
the toxicity of the causative agent of Huntington’s disease, the mutant huntingtin protein, due to 
impairment of autophagosome-lysosome fusion130. Furthermore, the mTOR inhibitor rapamycin 
reduces mutant huntingtin toxicity in vitro and in vivo via induction of autophagy131. 
Selective autophagic removal of damaged mitochondria, or mitophagy, is of particular 
interest within the context of cell death since loss of ΔΨm, which occurs following induction of 
MOMP by diverse death signals, targets mitochondria for mitophagy132. A pro-survival role for 
mitophagy in this context has been proposed based on the finding that the glycolytic enzyme 
GAPDH promotes clonogenic survival following MOMP partly due to a novel ability to enhance 
autophagy via Atg12 upregulation133. The recognition and targeting of depolarized mitochondria 
for autophagic removal is mediated by the kinase PINK1 and the E3 ligase Parkin132, 134-136. When 
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mitochondria are healthy, PINK1 translocates into the mitochondrial inner membrane via the 
general mitochondrial import machinery composed of the TOM and TIM23 complexes. There, it 
undergoes cleavage by the protease PARL, leading to its destabilization and degradation. 
However, since its import into the inner membrane and subsequent degradation relies on the 
mitochondrial membrane potential, loss of ΔΨm leads to rapid accumulation of PINK1 on the 
mitochondrial outer membrane and recruitment of the E3 ubiquitin ligase Parkin in a manner 
dependent on PINK1 kinase activity. Parkin recruitment to the MOM leads to ubiquitination of 
MOM substrates including VDAC1, and recruits the autophagy adaptor molecule p62/SQSTM1 to 
initiate mitophagy. Parkin and PINK1 mutations are implicated in the neurodegenerative disorder 
Parkinson’s disease, in which mitochondrial dysfunction is believed to play a casual role137. 
 
Autophagy as a tumor suppressor mechanism 
 Impaired autophagy has also been demonstrated to promote tumorigenesis, possibly 
through promoting genomic instability and inappropriate cell division126. The involvement of the 
autophagy machinery in cancer was initially revealed by the discovery in 1999 that beclin 1, 
mono-allelically deleted in 40-75% of sporadic human breast and ovarian cancers, is a candidate 
tumor suppressor110. In that study, the enforced expression of Beclin 1 in a human breast cancer 
cell line promoted autophagy, inhibited proliferation and clonogenicity, and impaired 
tumorigenesis in nude mice. Furthermore, the expression of endogenous Beclin 1 is lower in 
human breast carcinoma tissue compared to normal mammary epithelia. Subsequent generation 
of beclin 1 deficient mice revealed that homozygous loss of beclin 1 causes early embryonic 
lethality while heterozygous loss results in a high incidence of spontaneous tumors138. Loss of the 
second beclin 1 allele is not observed in these tumors, indicating that Beclin-1 is a 
haploinsufficient tumor suppressor. Though beclin 1 was initially discovered during the positional 
cloning of BRCA1, it was rediscovered independently in a yeast two-hybrid screen for interaction 
partners of BCL-2139. Importantly, ER-localized BCL-2, which is often overexpressed in cancers, 
can inhibit autophagy by binding to Beclin 1 via the Beclin 1 BH3 domain140. 
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Autophagy as a cell death mechanism 
 One of the first in vitro demonstrations that autophagy could indeed be a cell death 
mechanism appeared in 2004 with the report that RNAi-mediated knockdown of the essential 
autophagy regulators Beclin 1 and Atg7 protects against RIP1-dependent non-apoptotic death 
induced by caspase-8 inhibition in vitro141. That same year, another group reported that 
knockdown of Beclin 1 or Atg5 protects Bax-/-Bak-/- mouse embryonic fibroblasts against intrinsic 
death signals that induced extensive autophagy142. Then in 2007, the finding that degradation of 
larval salivary glands during Drosophila melanogaster metamorphosis depends on autophagy 
provided the first in vivo evidence that it may be a cell death mechanism143. In that study, 
autophagy inhibition via transgenic expression of autophagy inhibitory molecules or removal of 
autophagy genes results in the persistence of salivary gland cell fragments. Yet, autophagy does 
not account for all the processes of this developmental death. First, autophagy inhibition only 
delays tissue degradation by ~24 hours. Also, only the disappearance of cell fragments and not of 
whole intact cells is delayed. 
Due to its ability to degrade large portions of the cytoplasm, excessive activation of 
autophagy can be expected to cause cellular demise. Indeed, expression of Beclin-1 mutants that 
cannot be regulated by BCL-2 can kill cultured mammalian cells in vitro140 while transgenic 
expression in D. melanogaster larvae of a highly active mutant Atg1, an ortholog of mammalian 
ULKs, results in premature salivary gland degradation in vivo144. Yet, the in vivo evidence that cell 
death in a mammalian model organism is executed specifically by autophagy versus by another 
cell death modality is poor. For example, death induced by the hyperactive Atg1 mutant in D. 
melanogaster larvae is caspase-dependent and shows the morphological features of apoptosis, 
leading the authors to suggest that excessive autophagy is an inducer of apoptosis rather than a 
distinct form of cell death144. Although neuron-specific genetic deletion of Atg7 has been shown to 
protect against cell death in a mouse stroke model, the mode of death blocked by Atg7 loss in 
this scenario likewise displayed characteristic features of apoptosis145. This suggests that Atg7 is 
not killing via autophagy; rather, it is activating an apoptotic program either via autophagy or 
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another upstream mechanism. Therefore, it is still controversial whether autophagy does indeed 
constitute a cell death mechanism distinct from apoptosis and necrosis. 
1.4 Necrosis 
Programmed necrotic death: a new cell death paradigm 
 In their seminal report in 1972, Kerr and colleagues explained that they are coining a new 
term, “apoptosis”, in order to distinguish an apparently physiologically regulated form of cell death 
that had until then been called “necrobiosis” or “shrinkage necrosis” from “necrosis” or 
“coagulative necrosis”, which was widely regraded as accidental and unregulated13. Although it 
was acknowledged that there must exist a programmed form of cell death to counterbalance cell 
proliferation during development and in the adult, the morphological type of cell death described 
in almost all standard texts at the time was necrosis13. At that time, investigators believed that 
necrosis could not be responsible for physiological cell death as it always appeared to be caused 
by an irreversible disturbance of cellular homeostasis due to exposure to noxious stimuli13. And 
indeed, until the late 1980s, there was scant evidence to suggest otherwise. 
 In 1988, the observation that the death receptor ligand tumor necrosis factor (TNF) can 
induce either apoptosis or necrosis in vitro depending on the cell type provided the first clue that 
necrosis may also be subjected to molecular control8. Subsequent studies demonstrated that the 
necrotic response to TNF is mediated by increased generation of reactive oxygen species (ROS) 
by the mitochondria, in part due to increased glutamine metabolism that resulted in increased 
eletron flux through the mitochondrial electron transport chain146-148. A significant step in 
determining the mechanism of death receptor-induced necrosis was achieved with the finding that 
caspase inhibition switches the response of death receptor ligation from apoptosis to necrosis149, 
150. Then in 2000, details of the mechanisms regulating death receptor-induced necrosis began to 
emerge with the finding that necrosis triggered by the Fas death receptor ligand FasL requires its 
adaptor protein FADD and the enzymatic activity of the serine-threonine kinase RIP1151. The 
same study found that necrosis induced by the death receptor ligands TNF and TRAIL also 
require RIP1 kinase activity. The central role of the kinase activity of RIP1 in death receptor-
induced necrosis was demonstrated by the 2008 finding that it is the target of necrostatin-1 (nec-
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1)152, a potent and specific small molecule inhibitor previously discovered in 1995 by the same 
investigators to inhibit TNF-induced necrosis in vitro153. This type of regulated necrotic cell death 
was named “necroptosis” by these researchers153. In the 1995 report, nec-1 was also shown to 
protect against cerebral necrosis following ischemia-reperfusion in an in vivo stroke model153. In 
that same year, which proved to be a particularly fruitful one for the concept of a regulated form of 
necrosis, three groups independently reported that genetic deletion of Cyclophilin D, a key 
component of the mitochondrial permeability transition pore that leads to mitochondrial 
dysfunction and cell death following prolonged calcium overload, protects against necrosis 
following tissue ischemia-reperfusion in vivo and to specifically protect against necrosis but not 
apoptosis in vitro154-156. Thus, in less than two decades, programmed necrosis went from being a 
poorly-recognized biological phenomenon to a genetically regulated, physiologically relevant cell 
death subroutine. 
Though sometimes used to indicate programmed necrosis in general, “necroptosis” is 
defined biochemically as a type of cell death inhibitable by genetic or pharmacological ablation of 
the kinase activity of RIP1 and its interaction partner RIP3, and is primarily triggered by death 
receptor activation10. Reports from our lab and others also indicate the existence of RIP1- and 
RIP3-independent programmed necrosis elicited by intrinsic death stimuli including genotoxic 
stress9, oxidative stress157, and calcium dysregulation157. Unlike apoptosis, a linear pathway 
linking upstream death signals to downstream death effectors has not been established10. Indeed, 
physico-chemical stresses can serve as both necrosis initiators and effectors due to amplification 
by positive feedback loops generated by their deleterious effects on cellular physiology in general 
and on mitochondrial and lysosomal function in particular7, 10. Though these downstream death 
execution events are still an active area of investigation, ATP depletion, oxidative damage, 
dysregulated intracellular calcium homeostasis, non-caspase proteases, phospholipases, and 
lipoxygenases have all been implicated. 
 
Necroptosis 
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RIP1 is a member of the RIP family of serine-threonine kinases involved in innate and 
adaptive immunity and has both a kinase-dependent function in promoting apoptosis158 and 
necrosis151, 152, and a kinase-independent function in promoting cell survival and inflammation152, 
159, 160. It consists of an N-terminal kinase domain, a RIP homotypic interaction motif (RHIM), and 
a C-terminal death domain (DD)160. Ligation of the TNFR1 receptor induces a conformational 
change in the preformed trimeric receptor complex, leading to recruitment of the adaptor protein 
TRADD, which in turn recruits RIP1, the E3 ligases cIAP1 and cIAP2, TRAF2, and TRAF5; this 
constitutes the pro-survival complex I161. RIP1 is polyubiquitinated by cIAP1 and cIAP2, enabling 
it to act as a scaffold for assembling the TAK1-TAB2-TAB3 complex that initiates the canonical 
activation pathway of the pro-survival, pro-inflammatory transcription factor NF-κB162. 
Internalization of the ligand-bound TNFR1 and deubiquitination of RIP1 by the deubiquitinase 
CYLD158 changes the membrane-associated complex I into the cytosolic complex II consisting of 
RIP1, TRADD, FADD, and caspase-8161. Complex II was later discovered independently by three 
groups to also include RIP3163-165. Importantly, although RIP1 kinase activity mediates both TNF-
induced apoptosis158 and necrosis151, RIP3 kinase activity is only required for necrosis163. 
Activation of caspase-8 in this complex proteolytically inactivates RIP1 and RIP3 and initiates 
apoptosis166, 167. In the absence of caspase-8 activity, mutual RIP1 and RIP3 phosphorylation 
leads to the formation of the necrosome that constitutes the necroptosis activation complex160, 164. 
Although altered mitochondrial metabolism and excessive mitochondrial ROS production 
has been implicated in TNF-induced necrosis since the mid-1990s146-148, the nature and 
regulation of these and potentially other lethal events downstream of the necrosome remain 
poorly characterized. In line with previous findings implicating the mitochondria, RIP3 was 
reported to mediate TNF-induced necrosis by increasing mitochondrial ROS generation via 
upregulation of mitochondrial oxidative metabolism. Then in early 2012, a mechanistic 
breakthrough was revealed by two simultaneous reports from the laboratory of Xiaodong Wang 
that confirmed a central role for the mitochondria in necroptosis execution157, 168. In the first report, 
chemical library screening identified a compound named necrosulfonamide (NSA) that blocked 
necroptosis downstream of the necrosome168. NSA functions in this context by disrupting the 
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direct interaction between RIP3 and a novel binding partner, mixed lineage kinase domain-like 
protein (MLKL), via covalent modification of a MLKL cysteine residue. Following initiation of 
necroptosis, phosphorylated RIP3 recruits and phosphorylates MLKL, an event shown to be 
crucial for RIP3-mediated necrosis. In the second report, the authors show that MLKL, which 
does not possess enzymatic activity, acts as an adaptor protein to tether the necrosome to a 
splice variant of phosphoglycerate mutase 5 (PGAM5S) on the mitochondrial outer membrane via 
the other PGAM5 splice variant PGAM5L157. Once formed, the necrosome-PGAM5S complex 
drives mitochondrial fragmentation, an event implicated in cell death, through activation of an 
essential mediator mitochondrial fission, the GTPase Drp1. Activation of the PGAM5S-Drp1 
complex was proposed to constitute necroptosis complex III, which the authors described as a 
“mitochondrial attack complex”. Interestingly, complex III but not the necrosome was shown to be 
required for necrosis induced by dysregulated calcium homeostasis and ROS, raising the 
possibility that this complex and the induction of mitochondrial fission may be a central 
convergence point for both extrinsic (death receptor-mediated) and intrinsic necrotic signals. 
 
Programmed necrosis initiated by physico-chemical stress 
 In 1997, genetic deletion of the mammalian DNA damage repair enzyme poly(ADP-
ribose) polymerase 1 (PARP1) was reported to protect mice against cerebral ischemia-
reperfusion injury, providing another example of genetic regulation of necrosis in vivo169. 
Ischemia-reperfusion injury is an important clinical problem in which necrosis caused by loss of 
blood supply (ischemia) during a heart attack or stroke, or during solid organ transplantation, is 
exacerbated by the restoration of blood flow (reperfusion). PARP1 catalyzes the synthesis of 
poly(ADP-ribose) polymers on histones and other chromatin-associated proteins near DNA 
adducts to promote efficient recognition of damage DNA by repair machinery170. Overactivation of 
PARP1 consumes its substrate β-nicotinamide adenine dinucleotide (NAD+) leading to a 
depletion of cytosolic NAD+ and ATP levels170. Activation of PARP1 by ischemia-reperfusion has 
been attributed to oxidative DNA damage induced by the overproduction of ROS observed under 
this setting170. In a subsequent study, the same group demonstrated that DNA alkylation and 
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excitotoxicity induces PARP1-mediated mitochondrial dysfunction and caspase-independent cell 
death mediated by the release of AIF from the mitochondria171. Importantly, a 2004 study using 
apoptosis-incompetent Bax-/-Bak-/- cells demonstrated that following DNA alkylation-induced 
PARP1 activation and NAD+ depletion, cells that primarily used oxidative phosphorylation for ATP 
production are protected against ATP depletion and necrosis while those that derive ATP 
predominantly from glycolysis are sensitive172. Importantly, since cancer cells prefer to use 
glycolysis for ATP production even when conditions are permissible for oxidative 
phosphorylation173, this findings suggests the clinical efficacy of DNA alkylating chemotherapeutic 
agents may be due in part to tumor-specific induction of necrosis172. 
 The opening of the mitochondrial permeability transition pore (MPTP) is also implicated in 
the initiation of programmed necrosis triggered by oxidative stress, calcium overload, and 
ischemia-reperfusion injury91. Mitochondrial permeability transition describes the sudden increase 
in permeability of the mitochondrial inner membrane (MIM) to solutes with molecular mass up to 
1.5 kDa91. This is caused by the opening of the MPTP, a multicomponent complex spanning the 
mitochondrial outer membrane (MOM) and the MIM at the membrane contact sites91. Following 
opening of the MPTP, the osmotic pressure of the matrix leads to an influx of water and solutes, 
resulting in matrix swelling91. Since the surface area of the involuted MIM exceeds that of the 
MOM, matrix swelling can rupture the MOM174, which releases cytotoxic proteins from the IMS, 
causes mitochondrial dysfunction, and commits the cell to die91. 
The key factor responsible for MPTP opening is a large increase in mitochondrial matrix 
calcium concentration, with ROS also implicated to play an important role91. Mitochondrial 
calcium overload and excessive ROS production are both central to necrosis following ischemia-
reperfusion and are both a result of ATP depletion secondary to ischemia175. The MPTP pore has 
been proposed to consist of the voltage dependent anion channel (VDAC 1, 2, and 3) in the 
MOM, the adenine nucleotide translocase (ANT1 and 2) in the MIM, and cyclophilin D (CypD) in 
the mitrochondrial matrix6. Of these, only CypD has been shown to be an indispensible 
component of the MPTP. Three groups independently reported in 2005 that necrosis of neuronal 
and myocardial tissue caused by ischemia-reperfusion injury in the brain and heart can be 
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inhibited by genetic deletion of Ppif, the CypD-encoding gene154-156. In vitro experiments from 
those same studies showed that loss of CypD dramatically increased the level of calcium required 
to trigger MPTP opening. Significantly, though CypD was shown to be critical for necrosis, its 
deficiency did not impair the induction of apoptosis. In contrast, both VDACs and ANTs are not 
essential components of the MPTP. Mouse hepatocytes lacking both ANT isoforms displayed 
only a small increase in the level of calcium needed to trigger permeability transition176 while 
mouse fibroblasts deficient for all three VDAC isoforms showed no protection against calcium- 
and oxidative stress-induced MPTP opening and death177. Indeed, instead of showing resistance 
against intrinsic death signals, cells deficient for VDAC2 are more sensitive to cell death due to its 
inhibitory role in BAX activation178. 
 Finally, our lab reported in 2009 that DNA double-strand breaks induced by 
topoisomerase inhibitors in apoptosis-defective Bax-/-Bak-/- double knockout mouse embryonic 
fibroblasts (MEFs) trigger programmed necrosis in a RIP1-, PARP1, and CypD-independent 
manner9. We demonstrated that inhibition of transcription and translation protected against death, 
indicating that the initiation and execution of necrosis in this setting requires de novo gene 
expression. Furthermore, our study revealed that p53-mediated induction of the lysosomal 
protease cathepsin Q cooperated with increased production of ROS to execute necrosis. 
 
Executioner mechanisms of necrosis 
 It is currently unclear whether diverse death signals induce programmed necrosis via a 
common, well-defined sequence of executioner mechanisms10. Indeed, even in the case of the 
best characterized programmed necrosis pathway, necroptosis, the sequence of events leading 
from necrosome formation to eventual death is unclear. Nevertheless, most instances of 
programmed necrosis involve some or all of the following: ROS; mitochondrial and lysosomal 
dysfunction; dysregulated intracellular calcium homeostasis; and the activation of non-caspase 
proteases and phospholipases7, 10. Increasing evidence indicate that mitochondrial damage and 
dysfunction, induced either directly (e.g. by oxidative damage) or indirectly (e.g. calcium overload 
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secondary to energy depletion, as in the case of ischemia-reperfusion), also play central roles in 
the execution of programmed necrosis under diverse settings7, 91, 179. 
 Excessive mitochondrial ROS production and consequent oxidative damage is a central 
execution mechanism of programmed necrosis7. ROS are derivatives of molecular oxygen that 
are produced during normal physiological processes such as fatty acid catabolism and aerobic 
respiration180. Under healthy states, endogenous ROS production is countered by cellular 
antioxidant defences180. Excessive ROS production and/or impaired antioxidant capacity 
generates a deleterious state of oxidative stress, which damage all cellular constituents180. In 
most scenarios, intracellular ROS is primarily produced by the mitochondrial electron transport 
chain (ETC) as the unavoidable byproduct of aerobic respiration181. The leakage of electrons 
passing through the ETC leads to the one-electron reduction of O2 to O2•— (superoxide), which 
can then give rise to other ROS such as the hydroxyl radical181. Oxidative stress may contribute 
to cellular demise through, for example, inducing autocatalytic lipid peroxidation180. Among the 
ROS, superoxide and the hydroxyl radical are common initiators of this process, in which 
unsaturated membrane lipids are converted into polar lipid hydroperoxides180. This increases 
membrane fluidity, damages membrane-associated proteins, and compromises membrane 
integrity180. Compromised lysosomal membrane integrity can lead to the harmful release of 
lysosomal proteases while damage to the ER membrane can result in a deleterious release of ER 
calcium 179. With regard to proteins, oxidative damage can not only alter or abolish their functions 
but in some cases can also lead to increased ROS production180. For proteins containing iron-
sulfur (Fe-S) clusters, oxidative denaturation of the clusters can release redox-active ferrous iron 
into the cellular environment180. There, ferrous iron can catalyze the decomposition of hydrogen 
peroxide, which is poorly reactive, into the highly reactive hydroxyl radical, which can readily 
damage all nearby cellular constituents180. This decomposition of hydrogen peroxide is known as 
the Fenton reaction. In the case of the ETC, oxidative damage sustained by its components can 
increase electron leakage, creating a vicious cycle of ROS generation and oxidative damage181. 
 In pathological settings, elevated cellular calcium levels can contribute to necrosis though 
triggering mitochondrial membrane permeability transition as previously described, but also by 
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inducing ROS production, mitochondrial fragmentation, calcium-dependent calpain protease 
activation, and cytosolic phospholipase A2 (cPLA2) translocation7. In a normal, resting state, the 
concentration of free calcium in the cytosol and the mitochondrial matrix is ~ 10-100 nM; in 
contrast the ER calcium concentration is ~ 100-500 µM while that of the extracellular environment 
is in the mM range182, 183. This enables calcium to function as a second messenger in both the 
cytosol and mitochondria182. The maintenance of these steep concentration gradients depends on 
plasma and ER membrane ATPase transporters (respectively, plasma membrane Ca2+ ATPase 
or PMCA, and sarco/endoplasmic reticulum Ca2+ ATPase or SERCA), the plasma membrane 
sodium-Ca2+ exhanger (NCX), and on the integrity of cellular membranes182. Therefore, ATP 
depletion and oxidative damage sustained by cellular membranes, such as that seen during 
ischemia-reperfusion, can dramatically increase cytosolic and mitochondrial matrix calcium levels. 
The mitochondrial inner membrane potential drives calcium into the matrix through a 
highly selective inner membrane Ca2+ channel182. Under physiological conditions, upon ER 
calcium release, matrix [Ca2+] can reach several hundred µM while cytosolic levels can only reach 
1-2 µM183. Thus, mitochondria can buffer cytosolic calcium and tolerate a significant rise in matrix 
[Ca2+] before underoing permeability transition. Increased mitochondrial matrix calcium 
concentration upregulates the TCA cycle, leading to increased electron flow into the mitochondrial 
ETC and thus increased ROS production182. Pathological rises in calcium can lead to excessive 
ROS production, leading to oxidative stress. This is the main mechanism proposed for calcium-
induced mitochondrial ROS overproduction during programmed necrosis179. Interestingly, there 
are hints at another, non-mutually exclusive mechanism. Mitochondria are highly dynamic 
organelles that can build interconnected networks that continuously move along cytoskeletal 
tracks and frequently undergo fusion and fission184. Fusion and fission machinery shape the 
mitochondrial compartment in response to ever-changing physiological conditions184. The Drp1 
GTPas is a master regulator of mitochondrial fission and can be activated to promote fission by 
elevated cytosolic [Ca2+] via phosphorylation by Ca2+/calmodulin-dependent protein kinase Iα 
(CaMKIα) at serine 600185 and dephosphorylation by calcineurin at serine 637186. Increased 
mitochondrial fission has been shown to mediate increased ROS production following exposure 
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to hyperglycemia  in vitro, though the mechanism is unclear187. Importantly, activation of Drp1 by 
death receptor ligation, elevated calcium levels, and oxidative stress has been implicated in the 
execution of programmed necrosis157. This suggests elevated cytosolic [Ca2+] may also induce 
excessive ROS production as well as other potentially deleterious events during programmed 
necrosis through promoting mitochondria fission. 
 Calpains are ubiquitously and constitutively expressed cytosolic cysteine proteases 
activated by an increase in cytosolic calcium concentration7. Overactivation of calpains can result 
in proteolysis of the plasma membrane Na+/Ca2+ exchange pump involved in extrusion of calcium 
from the cytosol, thus further disrupting cellular calcium homeostasis7. Calpain overactivation has 
also been proposed to disrupt lysosomal membranes, leading to lysosomal membrane 
permeabilization (LMP) and the attendant deleterious release of lysosomal cathepsin proteases 
into the cytosol7. Significantly, following ischemic injury, activated µ-calpain was observed to 
localize at the membranes of damaged lysosomes in monkey hippocampal neurons188. 
Furthermore, cathepsin inhibitors were able to protect these neurons from ischemia-induced 
death189. 
Increased cytosolic calcium concentration also promotes translocation of cPLA2 to the 
nuclear, ER, and Golgi appartus membrane where it hydrolyzes arachidonate-containing 
phospholipids to release arachidonic acid7. Both free and esterified arachidonic acid are 
substrates for lipoxygenases that convert them into lipid hydroperoxides. Lipid hydroperoxidation, 
which can also occur via oxidative damage as described previously, compromises organelle and 
plasma membrane integrity. cPLA2 activation is implicated in TNF-induced necrosis while its 
deficiency has been reported to protect against brain ischemia7. 
Finally, lysosomes and cathepsins are also implicated in programmed necrosis. The 
“calpain-cathepsin” hypothesis has been previously discussed, as has data from our lab 
implicating cathepsin Q in executing DNA damage-induced programmed necrosis. Under normal 
conditions, the lysosome is also the sole intracellular location of redox-active ferrous iron before it 
is incorporated into the catalytic center of proteins or stored as ferritin179. Hydrogen peroxide can 
readily cross cellular membranes to enter the lysosome and generate hydroxyl radicals via the 
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Fenton reaction179. Importantly, the lysosome does not possess enzymes that detoxify hydrogen 
peroxide179. Involvement of lysosomal iron in necrosis is indicated by the ability of intralysosomal 
iron chelators to protect against oxidative stress-induced LMP and cell death. 
 
Physiological and pathological roles of programmed necrosis 
 Loss of function animals models have demonstrated the importance of key regulators of 
programmed necrosis in promoting tissue injury under diverse pathological conditions. Although 
Rip1-/- mice are not viable190 and tissue-specific knockout and kinase-dead knock-in have not yet 
been reported, its role in brain ischemia153, myocardial infarction191, and head trauma192 are 
indicated by the protective effects of necrostatin-1 administration in those scenarios . Rip3-/- mice 
are viable and protected from pancreatic acinar cell necrosis in a rodent acute pancreatitis 
model163. PARP1 loss also protects against acute pancreatitis193 while loss of CypD reduces 
tissue infarction in mouse models of stroke and myocardial infarction154-156. 
Though necrosis was traditionally viewed as a pathological form of cell death, the 
observation that naturally occuring motor neuron death may exhibit necrotic features provided an 
early indication that necrosis may also constitute a physiological cell death mechanism194. Then 
in 2011, three key reports provided evidence suggesting a physiological role for necroptosis 
during development as well as giving an answer to a conundrum in the cell death field195-197. The 
extrinsic pathway of apoptosis is initiated by the binding of a death ligand to its cognate plasma 
membrane death receptor, leading to the formation of the death-inducing signalling complex 
(DISC) previously discussed, with FADD, caspase-8, and the caspase-like regulator molecule 
FLIP all being components of this complex. Knockout of any of these three molecules results in 
embryonic lethality, with a failure in yolk sac vascularization and hematopoiesis198-200. It is difficult 
to attribute this phenotype to a defect in apoptosis, which typically leads to defects associated 
with excessive cells such as those seen with the Bax-/-Bak-/-65 and Bid-/-Bim-/-PUMA-/-73 mice. In 
2011, three independent groups of investigators showed that combined genetic deletion of 
caspase-8 and RIP3195, 196 or of FADD and RIP1197 results in normal embryonic development, 
indicating that the developmental defects and embryonic lethality caused by loss of FADD and 
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caspase-8 are due to a failure to suppress necroptosis. Furthermore, one of those groups also 
used RNAi-mediated knockdown of FLIP in Caspase-8 and Rip3 doubly-deficient mouse 
embryonic fibroblasts to demonstrate that a caspase-8-FLIP heterodimer inhibits RIP3-dependent 
necrosis196. 
It is currently unclear how an organism may benefit from being able to readily trigger 
necroptosis during development or adult life. Rip3-/- mice develop into healthy and fertile adults201, 
indicating that organisms can develop and live successfully without a functional necrosome. Still, 
the fact that there exists a molecular mechanism to suppress necroptosis during normal 
embryonic development suggests necroptosis may play roles that are essential for the welfare of 
the organism under specific, possibly adverse settings. The effect of necrotic death versus 
apoptosis on the immune system suggests one possible physiological function. With few 
exceptions, apoptosis in vivo is anti-inflammatory and produces immunological tolerance whereas 
necrosis triggers inflammation and an immune response179. Both apoptotic and necrotic cell 
corpses are efficiently cleared from surrounding tissue by professional and non-professional 
phagocytes. However, in the case of necrosis, the lack of organized chromatin condensation and 
loss of cellular membrane integrity results in leakage of pro-inflammatory factors (e.g. histones, 
the chromatin-associated protein HMGB1, DNA, and RNA) that are detected by and activate 
immune cells. This suggests that a cell may prefer a necrotic death in settings where an 
inflammatory response may be beneficial to the organism, such as in cases of pathogenic 
infection. In support of this, viral infections are known to initiate necroptosis179. For example, 
vaccinia virus infection induces the formation of the pro-necrotic RIP1-RIP3 complex164 and 
sensitizes cells to TNF-induced death in a RIP1-dependent manner202. Accordingly, RIP3-
deficient mice are resistant to vaccinia virus-induced hepatic inflammation and necrosis, but 
cannot effectively control viral replication164. Furthermore, the murine cytomegalovirus protein 
M45 disrupts RIP1-RIP3 interaction to inhibit necroptosis203,204. Importantly, viral infection of wild-
type mice is severely attenuated by a mutant M45 that cannot interact with RIP1-RIP3. 
Importantly, attentuation of viral infection is completely rescued in RIP3-deficient mice204. In 
aggregate, these studies demonstrate that viruses utilize inhibition of host cell necrosis as a 
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strategy to sustain viral replication, whereas host cells undergo necrosis as a way to clear viral 
infection. 
 
1.5 Significance 
 The past few decades have witnessed a paradigm shift in the field of cell death. The idea 
that apoptosis is the only form of programmed cell death has been challenged by the emerging 
evidence that necrosis can be as programmed as apoptosis. Characterization of pathways that 
initiate programmed necrosis is well under way while animal models are providing increasing 
insights into the physiological and pathological roles of programmed necrosis. Although the 
events and processes that ultimately result in cellular demise and the mechanisms of their 
activation by upstream death initiation events are unclear, these are also beginning to be 
elucidated. Whether diverse necrotic signals converge on a single sequence and set of execution 
mechanisms remains to be determined. Given the wide variety of pathologies in which 
programmed necrosis is implicated, a thorough understanding of the factors that influence the 
outcome of the life-or-death decision upon exposure to death stimuli can potentially open up 
broad new avenues for therpeutic intervention for many human injuries and diseases. Importantly, 
the evasion of apoptosis is a key hallmark of tumorigenesis; thus, delineation of programmed 
necrosis pathways and the factors that may contribute to resisting necrotic death will provide new 
strategies for the treatment of human cancers. 
 Oxidative stress is central to both the initiation and execution of programmed necrosis. In 
Chapter Two, I demonstrated that the transcription factor ΔNp63α protected against programmed 
necrotic death (PND) and enhanced long-term survival of apoptosis-defective cells in the face of 
intrinsic death signals via a previously unknown ability to control intracellular redox homeostasis 
by regulating glutathione metabolism. My findings from Chapter Two also established oxidative 
stress as a central determinant of death versus long-term survival following exposure to intrinsic 
death signals. In Chapter Three, I showed that in DKO MEFs, DSBs trigger an ATM/ATR/DNA-
PK-mediated DNA damage response that increased ROS production by upregulating the activity 
of complex III of the electron transport chain. 
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1.6 Figure Legends 
 
Figure 1.1 Cell death is categorized according to morphological features. Electron microscopy 
images of a normal (a), autophagic (b), apoptotic (c), and necrotic (d) cell. Scale bar = 1 µm. 
(Figure adapted from Edinger et al., (2004) Curr Opin Cell Biol. 16: 663-669) 
 
Figure 1.2 Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. 
(Figure adapted from Kim et al., (2006) Nat. Cell Biol. 8, 1348-58) 
 
Figure 1.3 Schematic depiction of the autophagy pathway and its core molecular machinery in 
mammalian cells. (Figure adapted from Yang et al., (2010) Curr Opin Cell Biol. 22:124-131) 
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1.7 Figures 
Figure 1.1 Morphological features of apoptosis, autophagy, and necrosis 
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damaged organelles and long-lived proteins in addition to
its catabolic role providing energy in times of famine. It has
been suggested that cells can die a ‘programmed’ death by
autophagy in which cells digest themselves to death as a
suicide strategy (reviewed in [8–10]). This idea is in direct
contradiction with the proven role of autophagy in many
different organisms as a survival mechanism during lean
times. Thus, the question emerges, is autophagy a survival
pathway, a suicide pathway or both in mammalian cells?
This review will discuss recent advances in our under-
standing of the biological relevance of programmed necro-
sis and the role of autophagy in determining cell fate and
will explore the idea that necrosis and autophagic death are
really two sides of the same coin.
Necrosis: not just an accident?
When caspases were originally identified as the mediators
of apoptosis, it was hypothesized that many of their
substrates were essential proteins whose destruction
ensured the inevitability of cell death. However, cas-
pase-independent cell death is observed in many systems
indicating that cells still die even if the executioner is
absent. Following an apoptotic stimulus, such as the
expression of Bax or treatment with tumor necrosis factor
(TNF) or Fas ligand, cells will die even in the presence of
non-specific caspase inhibitors such as zVAD-fmk or anti-
apoptotic molecules like Bcl-XL that prevent caspase
activation [2,4]. Under these conditions, cells that would
normally die by apoptosis exhibit all the hallmarks of
necrosis. In some cases, caspase-independent necrotic
cell death can be forestalled by treatment with antiox-
idants or by eliminating the activity of the protein kinase
RIP. These results led to the idea that necrosis could be
‘programmed’ — cellular signaling events initiated necro-
tic destruction that could be blocked by inhibiting dis-
crete cellular processes. A criticism of this concept of
664 Cell division, growth and death
Figure 1
Morphological features of autophagic, apoptotic and necrotic cells. (a) Normal, (b) autophagic, (c) apoptotic (d) and necrotic cells. Whereas the
morphologic features of apoptosis are well defined, the distinction between necrotic and autophagic death is less clear. The bioenergetic
catastrophe that culminates in cellular necrosis also stimulates autophagy as the cell tries to correct the decline in ATP levels by catabolizing its
constituent molecules. Thus, vacuolation of the cytoplasm is observed in both autophagic cells (b) and in cells stimulated to undergo
programmed necrosis (d). By contrast, ATP levels are maintained in normal (a) and apoptotic cells (c) consistent with the limited number of
autophagic vacuoles in their cytoplasm. The scale bar represents 1 mm.
Current Opinion in Cell Biology 2004, 16:663–669 www.sciencedirect.com
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Figure 1.2 Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 
subfamilies 
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Figure 1.3 Schematic depiction of the autophagy pathway and its core molecular 
machinery in mammalian cells. 
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inactivator BH3s in response to death induced by tBID–BIM–PUMA, 
whereas MCL-1 was only inactivated by NOXA (Table 1). One criti-
cal question is whether BCL-2 and BCL-XL are functionally equivalent. 
The anti-apoptotic activity of BCL-2 and BCL-XL against diverse death 
stimuli was differentially regulated by BAD, BMF, BLK and HRK (Fig. 7a, 
b). None of the inactivator BH3s were able to antagonize BCL-XL against 
staurosporine-induced apoptosis, whereas each of the BH3s, with the 
exception of NOXA, almost completely abolished the activity of BCL-XL 
in glucose-deprivation-induced death (Fig. 7b). BCL-2 was less opposed 
by inactivator BH3s compared with BCL-XL in tunicamycin- and thap-
sigargin-induced death (Fig. 7a, b). Although it has been reported that 
HRK interacts with both BCL-2 and BCL-XL (ref. 24), HRK selectively 
inhibited BCL-XL (Fig. 7a, b)
BMF was originally cloned as an MCL-1-interacting protein25, even 
though it did not bind as tightly as NOXA to MCL-1 (see Supplementary 
Information, Fig. S4b). The physiological relevance of MCL-1–BMF 
interaction was reflected by the ability of BMF to antagonize MCL-
1 in staurosporine-, etoposide- and thapsigargin-induced apoptosis 
(Fig. 7c). As both activator and inactivator BH3s could be activated by 
these death stimuli, our assays potentially reflected additive or syner-
gistic effects between the tested inactivator BH3s and those induced. 
Our data provided evidence that BCL-2, BCL-XL and MCL-1 are not 
functionally equivalent.
DISCUSSION
Although multidomain proapoptotic BAX and BAK are essential down-
stream effectors controlling the mitochondrion-dependent cell-death 
programme, they need to be activated by the activator BH3s — BID, 
BIM and PUMA. Contradictory to previous reports showing that bac-
terially expressed BIM and PUMA were unable to trigger cytochrome 
c efflux26–28, we observed potent cytochrome c releasing activity of both 
IVTT proteins. As <1 ng of BIM–PUMA was generated by IVTT, less 
than 1 nM of BIM–PUMA was sufficient to mobilize all the intrami-
tochondrial cytochrome c. This discrepancy may reflect misfolding of 
bacterially expressed BIM–PUMA. Alternatively, post-translational 
modification, such as phosphorylation, may be required to activate 
BIM–PUMA. The three isoforms of BIM exhibited comparable activ-
ity. Finally, the observation that the PUMA BH3 peptide is incapable 
of releasing cytochrome c further highlights the importance of using 
full-length molecules. Recently, cytosolic PUMA was proposed to dis-
place p53 from BCL-XL, allowing p53 to permeabilize mitochondria28. 
Notably, p53 is at least 1,000 times less potent than PUMA in inducing 
mitochondrial permeabilization29. Consistent with a previous report that 
PUMA was localized at the mitochondria30, we were able to utilize BAD 
or NOXA BH3 peptides to displace PUMA from BCL-XL or MCL-1 
from isolated mitochondria to release cytochrome c. Most importantly, 
PUMA effectively triggered cytochrome c efflux in p53 null cells (see 
Supplementary Information, Fig. S1e).
Heterodimerization between multidomain proapoptotic and anti-
apoptotic BCL-2s is one of the signature characteristics of the BCL-2 
family. However, functional correlation of this heterodimerization is 
ambiguous. BAK was reported to interact selectively with BCL-XL and 
MCL-1, but not BCL-2, BCL-W, and A1 (ref. 21). Nevertheless, both 
BCL-2 and BCL-XL inhibited BAK-dependent apoptosis in Bax-defi-
cient cells equally well (data not shown). Our studies clearly dem-
onstrate that BCL-2–BCL-XL–MCL-1 efficiently inhibits apoptosis in 
Bax, Bak DKO cells reconstituted with a BAX or BAK mutant that 
no longer interacts with BCL-2–BCL-XL–MCL-1. Therefore, anti-
apoptotic BCL-2s do not block apoptosis through direct inhibition 
of BAX–BAK. Indeed, the anti-death activity of anti-apoptotic BCL-
2s correlates well with their ability to sequester BAX–BAK activators 
(BID–BIM–PUMA). The competition for activator BH3s by multi-
domain anti-apoptotic and proapoptotic members may help explain 
why the ratio between these two multidomain subfamilies dictates the 
susceptibility to death. It is likely that the heterodimerization between 
multidomain proapoptotic and anti-apoptotic BCL-2s regulates other 
biological processes, such as calcium homeostasis31,32. Notably, the anti-
apoptotic BCL-2s display much higher affinity for activator BH3s com-
pared with proapoptotic BAX–BAK. The implication is that BAX–BAK 
will not be activated until all the hydrophobic pockets of anti-apoptotic 
BCL-2s are saturated with BH3s, thus providing a fail-safe mechanism 
to avoid unnecessary BAX–BAK activation. Interestingly, it seems that 
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Figure 6 BAD and NOXA synergize to trigger apoptosis by displacing BIM 
and PUMA from anti-apoptotic BCL-2 members to activate BAX and BAK. 
(a) Wild-type, Bax–Bak DKO MEFs, or wild-type MEFs stably expressing 
shRNA against Bim using pSUPER–RETRO system were transduced with 
BAD and/or NOXA expressing retrovirus. Cell death was quantified by 
Annexin-V staining 24 h post-infection. The values represent the mean ± s.
d. of three independent experiments; P = 0.0292 vector control versus Bim 
knockdown. (b) Puma+/–, Puma–/– or Puma–/– MEFs stably expressing shRNA 
against Bim using pSUPER–RETRO system were transduced with control 
MSCV retrovirus or BAD plus NOXA expressing retrovirus. Cell death was 
quantified by Annexin-V staining 24 h post-infection. The values represent 
the mean ± s.d. of three independent experiments; P = 0.0013 Puma+/– versus 
Puma–/–; P = 0.0053 Puma–/– versus Puma–/– with Bim knockdown. 
(c) Schematic representation of the mammalian core apoptotic pathways.
extracellular stresses relies largely on the elucidation of the
signaling network upstream of the Atg machinery.
Core molecular machinery
ULK complexes
The yeast serine/threonine kinase Atg1 plays a key role in
the induction of autophagy, acting downstream of the
target of rapamycin (TOR) complex 1 (TORC1). A
family of mammalian Atg1 proteins has been identified;
among these, unc-51-like kinases 1 (ULK1) and 2 have
the highest similarity with yeast Atg1 and appear to be
closely related. siRNA knockdown of ULK1 or ULK2
blocks autophagy in HEK293 cells [6!]. However,
ULK1"/" mice display normal autophagy in response
Mammalian autophagy overview Yang and Klionsky 125
Figure 1
Schematic depiction of the autophagy pathway and its core molecular machinery in mammalian cells. Mammalian autophagy proceeds through a
series of steps, including initiation at the PAS (phagophore assembly site), elongation and expansion of the phagophore, closure and completion of the
autophagosome, autophagosome maturation via docking and fusion with an endosome and/or lysosome, breakdown and degradation of the
autophagosome inner membrane and cargo, and recycling of the resulting macromolecules. Regulatory components for autophagy induction include
the ULK1 and ULK2 complexes that contain various Atg proteins (light blue box at left) that are required for autophagy. The association of mTORC1
with this complex and the activity of mTORC1 depend on the nutrient status. Under nutrient-rich conditions, mTORC1 is associated with the ULK1 and
ULK2 complexes, and phosphorylates ULK1, ULK2, and mAtg13; upon inactivation of mTORC1 by nutrient starvation, mTORC1 dissociates, mAtg13,
ULK1 and ULK2 are partially dephosphorylated, and activation of ULK1 and ULK2 promotes phosphorylation of FIP200. There are at least three class
III PtdIns3K complexes (light red box at right) that are involved in autophagosome formation or clearance. The Atg14L (Atg14L–Beclin 1–hVps34–p150)
and UVRAG (UVRAG–Beclin 1–hVps34–p150) complexes are required for autophagy, whereas the Rubicon complex (Rubicon–UVRAG–Beclin 1–
hVps34–p150) negatively regulates autophagy. Ambra1 and Bif-1 are essential for the induction of autophagy, through direct interaction with Beclin 1
and UVRAG, respectively, whereas Bcl-2 binds to Beclin 1 and disrupts the Beclin 1-associated hVps34 complex, thereby inhibiting autophagy.
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2.1 Abstract 
Despite the importance of ROS in executing cell death, its regulation remains elusive. 
Here, we report that p63 dictates the homeostasis of intracellular redox through transcriptional 
controls of glutathione metabolism genes. Overexpression of ΔNp63α, the major isoform of p63, 
protected cells from oxidative stress induced by thiol or lipid oxidants, DNA damage, and anoikis. 
Conversely, deficiency of ΔNp63α increased oxidative stress. Strikingly, overexpression of 
ΔNp63α rendered clonogenic survival of p53-/-Bax-/-Bak-/- triple-knockout cells against DNA 
damage. Along the same line, co-expression of BCL-2 and ΔNp63α, which abrogated apoptosis 
and oxidative stress, respectively, produced clonogenic survival against matrix detachment and 
disrupted the luminal clearance of mammary acini. In conclusion, inhibiting apoptosis only offers 
short-term survival, whereas a simultaneous blockade of apoptosis and oxidative stress is central 
for long-term survival.  
 
2.2 Introduction 
Proper execution of cell death ensures normal biological processes, and its deregulation 
causes human illness, ranging from cancer to neurodegenerative disorders1. Three forms of cell 
death have been recognized based on morphological features: apoptosis, autophagic cell death, 
and necrosis2. Among the three distinct forms of cell death, apoptosis is best studied. The BCL-2 
family proteins are central regulators of apoptosis3. Genetic loss-of-function studies reveal an 
essential axis of upstream “activator” BH3-only molecules and downstream BAX and BAK in 
activating mitochondrion-dependent apoptosis4-7. In response to apoptotic signals, the “activator” 
BH3-only molecules, including BID, BIM, and PUMA, trigger the homo-oligomerization of 
multidomain proapoptotic BAX and BAK to permeabilize mitochondria, leading to the efflux of 
cytochrome c which in turn initiates the assembly of apoptosome complex for caspase activation5-
10. Although apoptosis has long been considered as the major cell death mechanism required for 
the successful development and maintenance of tissue homeostasis in metazoans2, double 
deficiency of Bax and Bak only disrupts the development and homeostasis in restricted sets of 
tissues4, suggesting the existence of BAX and BAK-independent cell death mechanism(s) in 
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maintaining the tissue homeostatic state. To explore this cell death conundrum, we utilized 
transformed Bax-/-Bak-/- double-knockout (DKO) mouse embryonic fibroblasts (MEFs) and 
discovered that these apoptosis-deficient cells underwent a regulated form of necrotic cell death 
in response to DNA damage induced by topoisomerase inhibitors11. Surprisingly, this type of 
necrotic cell death requires active transcription/translation11, which is in stark contrast with a 
general perception that necrosis is not programmed. As this DNA damage-induced “programmed 
necrotic death” (PND) does not require RIP1, it is distinct from TNF-induced “necroptosis”12 (fig. 
S2.1). Furthermore, we have reported that this death is independent of caspases, mitochondrial 
permeability transition pore (PTP), autophagy, or PARP11. Notably, DNA alkylation induces 
PARP-dependent necrotic death whereas double-strand DNA breaks induces PARP-independent 
necrotic death in DKO cells11,13. Mechanistically, we delineated a p53-cathepsin axis that 
cooperates with ROS (reactive oxygen species) to activate PND in DKO cells undergoing double-
strand DNA breaks11. By analogy to DNA damage-induced cell death, it was reported that 
inhibition of apoptosis by BCL-2 is insufficient to provide long-term clonogenic survival against 
anoikis14,15, a form of cell death that is induced by detachment from extracellular matrix in 
anchorage-dependent cells. Remarkably, antioxidant cooperates with BCL-2 to enhance 
clonogenic survival and prevent the luminal clearance of acini in three-dimensional culture of 
mammary epithelial cells15. Thus, although apoptosis is the fastest mechanism for eliminating 
cells in response to death stimuli, inhibition of apoptosis is insufficient to render long-term 
clonogenic survival, which is indeed required for the prevention of pathological loss of cells during 
disease processes. ROS is one of the most important second messengers in executing necrosis16 
and appears to play a critical role in abrogating long-term clonogenic survival. Despite its 
essence, how ROS is regulated remains largely uncharacterized.  
 
2.3 Results 
Because our data indicated that genotoxic stress-induced necrotic death requires active 
transcription11, we hypothesized that ROS could be regulated by transcription factor(s). A series 
of gain-of-function and loss-of-function screens identified p63, the primordial member of the p53 
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family17, as a master transcriptional regulator of ROS. Overexpression of the major isoform of 
p63, ΔNp63α, prevented etoposide-induced ROS accumulation in transformed DKO MEFs (Fig. 
2.1A). Three ROS-sensitive dyes were employed to interrogate intracellular ROS levels—
H2DCFDA, a broad-spectrum ROS indicator; dihydroethidium (DHE), a specific indicator for 
superoxide; and MitoSOX Red, a specific indicator for mitochondrial matrix superoxide as 
mitochondria are the major source of ROS within the cells16,18. Consistent with our previous 
identification of p53 and ROS as two independent effectors in executing necrotic death11, 
overexpression of a dominant negative mutant of p53 (p53 DN) failed to block ROS induction 
triggered by genotoxic stress (Fig. 2.1 A). Overexpression of either ΔNp63α or p53 DN provided 
DKO cells a short-term survival advantage against etoposide (Fig. 2.1 B). Importantly, co-
expression of both ΔNp63α and p53 DN enhanced clonogenic survival of DKO cells against 
etoposide (Fig. 2.1 C). To further demonstrate p53-independent regulation of ROS by ΔNp63α, 
p53-/-Bax-/-Bak-/- triple-knockout (TKO) MEFs were generated. Transformed p53-/-Bax-/-Bak-/- TKO 
MEFs were more resistant to DNA damage than Bax-/-Bak-/- DKO MEFs (fig. S2.2). However, 
TKO cells were eventually killed by DNA damage due to ROS-induced oxidative stress that was 
abrogated by antioxidant N-acetyl-L-cysteine (NAC) or diphenyleneiodonium (DPI) (fig. S2.3). 
Strikingly, overexpression of ΔNp63α protected TKO from etoposide-induced ROS accumulation 
and cell death (Fig. 2.1, D to F, and fig. S2.4). It was reported that another p63 isoform, TAp63, is 
induced by DNA damage in MEFs19 and deficiency of TAp63 but not p53 protects oocytes from 
ionizing irradiation-induced cell death20. Of note, we could only detect TAp63 but not ΔNp63 in 
MEFs by PCR (fig. S2.5). In fact, the level of TAp63 in MEFs was too low to be detected by 
immunoblots. Knockdown of TAp63 in DKO or TKO MEFs had no effect on etoposide-induced 
cell death (fig. S2.5), indicating that endogenous TAp63 is not involved in DNA damage-induced 
necrotic death and ΔNp63α does not inhibit oxidative stress through antagonizing endogenous 
TAp63. In summary, our gain-of-function approach discovered a previously unrecognized role of 
ΔNp63α in regulating oxidative stress. Moreover, the inhibition of oxidative stress by ΔNp63α 
rendered clonogenic survival of p53-/-Bax-/-Bak-/- TKO cells against DNA damage. 
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Oxidative stress is caused by an imbalance between the production of ROS and the 
ability of detoxifying reactive intermediates16,21. If ΔNp63α prevents DNA damage-induced 
oxidative stress by increasing antioxidant capacity, ΔNp63α should also protect cells against 
exogenous oxidants. Indeed, overexpression of ΔNp63α protected wild-type cells from thiol 
oxidant diamide and lipid oxidant tert-butyl hydroperoxide (TBH) (Fig. 2.2A). These findings are 
consistent with a notion that ΔNp63α alters the intracellular redox state by increasing the 
antioxidant capacity of cells and thereby protects cells against diverse sources of oxidative stress. 
Given that glutathione is the major antioxidant produced by the cell and plays a central role in 
regulating intracellular redox state16,21,22, one testable thesis is that ΔNp63α mitigates oxidative 
stress through transcriptional regulation of glutathione metabolism genes. Glutathione is 
synthesized in two sequential steps, catalyzed by glutamate-cysteine ligase (GCL) and 
glutathione synthetase (GSS), respectively22 (Fig. 2.2B). It exists in both reduced (GSH) and 
oxidized (GSSG) states22. GSH can act as a free radical scavenger and an inhibitor of lipid 
peroxidation. GSH also participates in the detoxification of hydrogen peroxide through various 
glutathione peroxidases (GPX) (Fig. 2.2B). During this process, GSH is oxidized to GSSG, which 
can then be recycled back to GSH through the action of glutathione reductase (GSR) at the 
expense of reduced nicotinamide adenine dinucleotide phosphate (NADPH). NADPH can be 
generated by several enzymes, including isocitrate dehydrogenase 2 (IDH2). Interestingly, gene 
expression profiling revealed that genes involved in glutathione redox pathway were upregulated 
in ΔNp63α-overexpressing cells both before and after DNA damage (fig. S2.6). Quantitative RT-
PCR analysis confirmed that GCLC (the catalytic subunit of GCL), GSS, IDH2, and GPX2 were 
upregulated by ΔNp63α (Fig. 2.2C). Hence, it appears that DNp63a orchestrates a genetic 
program to integrate the biosynthesis of glutathione, the utilization of GSH as an antioxidant, and 
the regeneration of GSH from GSSG (Fig. 2.2B), the outcome of which would increase the ratio of 
GSH to GSSG, an indicator of a more reduced intracellular redox state. Indeed, overexpression 
of ΔNp63α significantly increased the GSH/GSSG ratio in cells both before and after etoposide 
treatment (Fig. 2.2D). The functional significance of these ΔNp63α-induced glutathione 
metabolism genes in regulating necrotic cell death was interrogated by siRNA-mediated 
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knockdown (fig. S2.7). Deficiency of GCLC, GSS, GPX2, or IDH2 compromised, to varying 
extents, the ability of ΔNp63α to protect DKO cells against DNA damage (Fig. 2.2, E to H). Of 
note, deficiency of these genes also enhanced etoposide-induced cell death in control DKO cells, 
but to a lesser degree (Fig. 2.2, E to H), supporting the involvement of oxidative stress in this 
form of cell death. Collectively, our data demonstrate that p63 orchestrates a tightly coupled 
glutathione metabolic circuit to alleviate oxidative stress and thereby protects apoptosis-defective 
cells from ROS-mediated necrotic cell death (Fig. 2.2B). 
To investigate the role of endogenous ΔNp63α in regulating redox homeostasis, 
knockdown of p63 using a published shRNA23 was performed in cell lines where ΔNp63α is the 
predominant isoform (Fig. 2.3A). In agreement with our gain-of-function study, knockdown of 
endogenous ΔNp63α led to increased intracellular ROS levels in both human mammary epithelial 
cell line MCF-10A and human cervical carcinoma cell line ME-180 (Fig. 2.3B). Furthermore, 
knockdown of p63 using siRNA or miR30-based shRNA also increased ROS in these cells (Fig. 
S2.8). Importantly, quantitative RT-PCR demonstrated that deficiency of ΔNp63α downregulated 
GCLC, GSS, IDH2, and GPX2 (Fig. 2.3C)—the same set of genes that was upregulated by 
ΔNp63α (Fig. 2.2C). Of note, GSR was suppressed by the loss of endogenous ΔNp63α but not 
induced by the overexpression of ΔNp63α (Fig. 2.3C and data not shown), which might reflect 
cell type-specific regulation. Consistent with the downregulation of glutathione metabolism genes 
caused by the knockdown of ΔNp63α, the GSH/GSSG ratio was reduced in cells deficient for 
ΔNp63α (Fig. 2.3D), indicating a more oxidized intracellular redox state. Consequently, deficiency 
of ΔNp63α enhanced diamide-induced cell death, which was protected by the antioxidant NAC 
(Fig. 2.3E). Furthermore, deficiency of ΔNp63α sensitized cells to chemotherapeutic agent-
induced cell death (fig. S2.9). Altogether, our loss-of-function studies demonstrate an important 
role of endogenous ΔNp63α in gauging redox homeostasis. 
The observation that antioxidant and anti-apoptotic BCL-2 work in concert to promote 
long-term clonogenic survival against matrix detachment15 prompted us to investigate whether 
p63 can mitigate oxidative stress associated with anoikis and whether p63 can cooperate with 
BCL-2 to prevent the luminal clearance of acini in three-dimensional culture of MCF-10A cells. 
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Overexpression of ΔNp63α protected MCF-10A cells from anoikis, but to a lesser degree than 
BCL-2 (Fig. 2.4A). Importantly, overexpression of ΔNp63α but not BCL-2 prevented ROS 
induction in cells undergoing anoikis (Fig. 2.4B). Because BCL-2 profoundly blocked anoikis up to 
5 days, the combined effect of BCL-2 and ΔNp63α was not evident in short-term death assays 
(Fig. 2.4A). To investigate long-term survival in response to the loss of matrix attachment, MCF-
10A cells were seeded onto reconstituted basement membrane under conditions that enable the 
formation of three-dimensional acini where the inner, matrix-deprived cells are eliminated to 
facilitate lumen formation14,15. Overexpression of either BCL-2 or ΔNp63α only weakly whereas 
co-expression of BCL-2 and ΔNp63α markedly inhibited luminal clearance (Fig. 2.4, C and D). 
Luminal clearance of MCF-10A acini was evident within two weeks after seeding, whereas co-
expression of BCL-2 and ΔNp63α near completely blocked luminal clearance for up to a month 
(Fig. 2.4, C and D). Importantly, overexpression of ΔNp63α but not BCL-2 suppressed ROS 
accumulation in the matrix-deprived luminal cells (Fig. 2.4E). 
We presented evidence that ΔNp63α enhances endogenous antioxidant capacity through 
a coordinated regulation of glutathione metabolism genes. Among these identified ΔNp63α 
targets, GPX2 is the only reported direct transcriptional target of ΔNp63α24. It is conceivable that 
ΔNp63α may regulate the remaining targets directly or indirectly. Since Nrf2 is the most 
recognized transcription factor that controls the expression of many antioxidant genes, including 
GCLC25,26, and Nrf2 mRNA was slightly induced by ΔNp63α (fig. S2.10), we investigated whether 
ΔNp63α regulates GCLC through Nrf2 and whether Nrf2 is required for the antioxidant effect of 
ΔNp63α. Although knockdown of Nrf2 partially reduced GCLC (fig. S2.10), ΔNp63α-mediated 
upregulation of GCLC was not affected by the loss of Nrf2 (fig. S2.10). Accordingly, the protective 
effect of ΔNp63α against DNA damage-induced necrotic death was not affected by the deficiency 
of Nrf2 (fig. S2.10). These data not only illustrate an Nrf2-independent regulation of GCLC by 
ΔNp63α but also indicate that ΔNp63α is a bona fide central regulator of glutathione biogenesis. It 
remains to be determined how ΔNp63α integrates the glutathione metabolic program. 
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2.4 Discussion 
 Here, we report that ΔNp63α prevents oxidative stress and cooperates with apoptotic 
inhibition to promote long-term cellular survival against DNA damage and extracellular matrix 
detachment, highlighting the quintessence of suppressing oxidative stress in promoting long-term 
survival. Foreseeably, inhibition of oxidative stress may be especially critical to the wellbeing of 
long-lived cells such as stem cells. Notably, ΔNp63α is important in maintaining the stem cell 
populations of stratified epithelia17,27. In addition to sustaining the proliferative capacity of 
epithelial stem cells27, ΔNp63α may also promote stem cell survival through its antioxidant 
function. p63+/- mice have a shortened life span and display features of accelerated aging, and 
p63-deficient cells exhibit heightened cellular senescence28, all of which could be caused by 
oxidative damage18 and may be linked to oxidative stress resulted from the loss of ΔNp63α. In 
contrast to the tumor suppressor function of p53, ΔNp63α has been implicated as an oncogene 
and is frequently amplified and/or overexpressed in human squamous cell carcinoma of the lung 
and head and neck17,29. Because cancers often have an increased demand for antioxidant 
capacity compared to normal tissues likely due to inherent metabolic derangements that increase 
ROS production21, the Nrf2 antioxidant program has thus been shown to contribute to 
tumorigenesis30. By analogy, ΔNp63α might promote tumorigenesis by reducing oxidative stress.  
Although a detailed blueprint of the core apoptotic pathway has been formulated through 
biochemical and genetic studies over the past two decades, we are still unable to fully rescue 
cells from most death stimuli. The identification of oxidative stress as a critical mechanism 
compromising long-term survival of apoptosis-defective cells likely open new avenues for the 
therapeutic intervention aimed at preventing cellular loss during pathological processes. 
Conversely, targeting the antioxidant pathway may hold promise for the future development of 
anticancer therapeutics to eliminate cancer cells that evade apoptotic checkpoints.  
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2.5 Materials and Methods 
Plasmid construction, retrovirus production, and siRNA 
Murine ΔNp63α was dually tagged with FLAG and HA at the N-terminus and cloned into MSCV-
IRES-Puro or tagged with HA at the N-terminus and cloned into MSCV-IRES-GFP. A dominant 
negative mutant of p53 (aa 1-14 and aa 303-390) was dually tagged with FLAG and HA at the N-
terminus and cloned into MSCV-Puro (Clontech). Human BCL-2 was cloned into MSCV-IRES-
GFP or MSCV-Puro. Retrovirus-mediated knockdown constructs were generated using 
pSuperior-Retro-Puro according to the manufacture’s instructions (Oligoengine). The target 
sequence of shRNA against mouse p63 is 5’-AGCACACGATCGAAACGTA-3’. The target 
sequence of scramble shRNA is 5’- GCGCGCTTTGTAGGATTCG-3’. The production of 
retroviruses was described previously 6. Lentivirus-mediated knockdown constructs for human 
p63 and GFP were previously described 23, 31. All constructs were confirmed by DNA sequencing. 
Lentiviral tetracycline-inducible miR30-based shRNA against human p63 was obtained from 
Open Biosystems. The target sequence is 5’-TCCGAGCTATGTCAGTACTATT-3’. To induce the 
expression of shRNAmir, cells were treated with 2 µg/ml doxycycline (Sigma) for 3 days. 
Lentivirus was produced by cotransfection with pCMVDR8.2 and pHCMV.VSVG using 
Lipofectamine 2000 (Invitrogen). siRNA oligos were reverse-transfected using LipofectamineTM 
RNAiMAX (Invitrogen) to a final concentration of 10 or 20 nM. The siRNA oligos were purchased 
from Ambion Silencer Select oligos (Applied Biosystems) or Dharmacon: mouse IDH2 #1, 5’-
AGACUGACUUCGACAGGAAtt (Ambion s114463); mouse IDH2 #2, 5’-
GGAAUAAGAUCUGGUAUGAtt (Ambion 95489); mouse GCLC #1, 5’-
CGGUAUGACUCAAUAGAUAtt (Ambion s66718); mouse GCLC #2, 5’- 
GGGUGAUCCUCUCAUACAAtt (Ambion s201400); mouse GSS #1, 5’-
GCCCAGUCAGUAUAAUUCAtt (Ambion s67110); mouse GSS #2, 5’-
CCAUCAAAAAGGACGACUAtt (Ambion s67112); mouse GPX2 #1, 5’-
UCAAUGAGCUGCAAUGUCG (Dharmacon siGenome-02); mouse GPX2 #2 5’-
CAACUACCCGGGACUACAA (Dharmacon siGenome-03); mouse Nrf2, 5’-
CAUUUUUACUCAUCGAUCUtt (Ambion s70523); mouse p63, 5’-CCACCGAACUGAAGAAGCU 
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(Dharmacon siGenome-04); human p63, 5’-CGACAGUCUUGUACAAUUU (Dharmacon 
siGenome-08); mouse RIP1 #1, 5’-GGUGGUACCCUUUACUACAtt (Ambion s72975); mouse 
RIP1 #2, 5’-GGAUUUGGAACUACAGGUAtt (Ambion s72977); Ambion Silencer Select Negative 
Control #1; Dharmacon siGenome Negative Control #2. 
 
Cell culture and viability assays 
SV40-transformed Bax-/-Bak-/- double-knockout (DKO) mouse embryonic fibroblasts (MEFs) were 
previously described 6. E1A/Ras and c-Myc/Ras transformation was performed by infecting 
primary MEFs within the first 2 passages with retrovirus expressing E1A-IRES-Ras or c-Myc-
IRES-Ras as described previously 32. For E1A/Ras transformation, primary MEFs were generated 
from E12.5 Bax-/-Bak-/- DKO embryos and E12.5 p53-/-Bax-/-Bak-/- triple-knockout (TKO) embryos. 
E12.5 p53-/-Bax-/-Bak-/- TKO MEFs were transformed with SV40 as described previously 6. ME-
180 and MCF-10A cell lines were obtained from ATCC and cultured according the instructions. 
To induce anoikis, cells were grown on poly-HEMA (Sigma)-coated 6 well plates in the presence 
of 1% methylcellulose (Sigma). Cell death was quantified by annexin-V (BioVision) or propidium 
iodide (Sigma) staining, followed by flow cytometric analysis using either a FACSCalibur (BD 
Biosciences) or a LSRFortessa (BD Biosciences). Data were analyzed using CellQuest Pro (BD 
Biosciences) or FACSDiva (BD Biosciences).  P values for statistical analysis were obtained 
using Student's t test. 
 
Measurement of ROS 
Production of ROS was monitored by flow cytometric analysis using the redox-sensitive dyes. 
Cells were incubated with 1 µM 2’,7’-dichlorofluorescein diacetate (H2DCFDA, Invitrogen), 1 µM 
5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (CM-H2DCFDA, Invitrogen), or 1 
µM dihydroethidium (DHE, Invitrogen) at 37°C for 30 minutes, or with 2.5 µM MitoSOX Red 
(Invitrogen) at 37°C for 10 minutes. Oxidation of the ROS-sensitive dyes was quantified by flow 
cytometric analysis using either a FACSCalibur (BD Biosciences) or a LSRFortessa (BD 
Biosciences). Median fluorescence in the appropriate detection channels was assessed by 
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FlowJo (Tree Star). Fold induction of ROS was determined by dividing the median fluorescence 
of experimental samples with that of control samples. P values for statistical analysis were 
obtained using Student’s t-test. 
 
Clonogenic assays 
SV40-transformed MEFs were treated with etoposide (10 µg/ml) for 14 hours. E1A/Ras- and c-
Myc/Ras-transformed p53-/-Bax-/-Bak-/- TKO MEFs, transduced with retrovirus expressing GFP or 
GFP-IRES-ΔNp63α, were subjected to MoFlo (Beckman Coulter) sorting for GFP-positive cells 
before treatment with etoposide for 9 hours. 5 x 104 or 105 cells were washed with PBS and 
plated in 24-well tissue culture plates. Colonies were fixed with methanol and stained with 0.5% 
crystal violet in 25% methanol after 10-12 days.  
 
Reverse transcription and quantitative PCR  
Total RNA was extracted from cells using TRIZOL (Invitrogen) according to the manufacturer’s 
instructions.  Reverse transcription was performed with oligo-dT plus random decamer primers 
(Ambion) using Superscript II (Invitrogen). Quantitative PCR was performed with SYBR green 
master mix (Applied Biosystems) in duplicates using the indicated gene specific primers. For 
TaqMan probes, quantitative PCR was performed with TaqMan PCR Master Mix (Applied 
Biosystems). Quantitative PCR was performed on an ABI Prism 7300 sequence detection system 
(Applied Biosystems) or a ViiA 7 Real-Time PCR System (Applied Biosystems). Data were 
analyzed as described previously by normalization against GAPDH or 18S rRNA that was 
detected using TaqMan probes (Applied Biosystems)11. Primers for qRT-PCR are listed as 
follows: mouse p63 pan-isoform, 5’- CCTTTCCGTCAGAATACACACGGA-3’ and 5’- 
GTTTCTGAAGTAGGTGCTGGTGCT-3’; mouse p63 TA isoform, 5’- 
CCTATATGCTCAGTACAGCCCATCG-3’ and 5’- CTATTCTGTGCGTGGTCTGTGTTGT-3’; 
mouse p63 ∆N isoform, 5’- TCTTAGAAGATTCGCAGCGCAAGG-3’ and 5’- 
CTATTCTGTGCGTGGTCTGTGTTGT-3’; mouse GCLC, 5’-TACACCTGGATGATGCCAACGA-3’ 
and 3’-GTCAACCTTGGACAGCGGAATG; mouse GSS, 5’-CCTGATGCTAGAGAGATCTCGTGC 
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and 3’-CTCTCTCCTCACTGTCCTTCAGC; mouse IDH2, 5’-CCTGATGACATCTGTGCTGGTCT 
and 3’-GAGCTCTGTCCAGGTTGCTCTT; human GSS, 5'-GACCAGCGTGCCATAGAGAATGA 
and 3’-CATGTGACCTCTCCAGCAGTAGAC; human IDH2, 5’-
GATGGGAAGACGATTGAGGCTGA and 3’-TCAGGAAGTGCTCGTTCAGCTT; human GPX2, 5'-
TCTATGACCTCAGTGCCATCAGC and 3'-CCAGGACGGACATACTTGAGACTG; human GSR, 
5'-CCAACGTCAAAGGCATCTATGCAG and 3'-ATCTTCCGTGAGTCCCACTGTC; mouse Nrf2, 
5’-ATCCAGACAGACACCAGTGGATC-3’ and 5’-CAAACTTGCTCCATGTCCTGCTC-3’. The 
TaqMan probes for mouse GPX2 (TaqMan Assay ID Mm00850074_g1) and human GCLC 
(TaqMan Assay ID Hs00155249_m1) were obtained from Invitrogen. 
 
Three-dimensional culture of MCF-10A and indirect immunofluorescence microscopy 
MCF-10A cells were seeded onto reconstituted basement membrane (Matrigel) under conditions 
that enable formation of three-dimensional acini and were then assessed by indirect 
immunofluorescence microscopy as previously described33, 34. Briefly, 104 cells were seeded onto 
one chamber of a 4-well chamber slide pre-coated with Matrigel (BD Biosciences). After 31 days, 
cells were fixed using 4% paraformaldehyde (Fisher) and permeabilized using 0.5% Triton X-100, 
and sequentially incubated with anti-Laminin-5 (D4B5, EMD Millipore), Alexa Fluor 568 
conjugated goat anti-mouse IgG (Invitrogen), anti-GFP (ab13970, Abcam), Alexa Fluor 488 
conjugated goat anti-chicken IgG (Invitrogen), and nuclear stain 4,6-diamidino-2-phenylindole 
(DAPI, Sigma).  Images were acquired using the Leica TCS SP5-II Confocal Upright and the 
PerkinElmer UltraVIEW ERS confocal microscopes at the Molecular Cytology Core Facility at the 
Memorial Sloan-Kettering Cancer Center and analyzed by MetaMorph software (Molecular 
Devices). Cellularity of the equitorial cross-sections was scored as clear (~0-25% of the luminal 
space filled with cell nuclei), mostly clear (~25-50% cellularity), mostly filled (~50-75% cellularity), 
and filled (~75-100% cellularity). To measure ROS levels, three-dimensional culture of MCF-10A 
cells after 6-8 days were incubated with Hank’s Balanced Salt Solution (HBSS, Invitrogen) 
containing 5 µM dihydroethidium (DHE, Invitrogen) and 3 µg/ml Hoechst 33342 (Invitrogen) at 
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37°C for 30 minutes in a humidified 5% CO2 incubator, washed once with HBSS, then 
immediately imaged using the Leica TCS SP5-II confocal microscope. 
Reagents, antibodies, and immunoblot analysis 
Chemicals used are listed as follows: etoposide (Sigma), diamide (Sigma), tert-butyl 
hydroperoxide (Sigma), diphenyleneiodonium (Sigma), doxorubicin (Sigma), cisplatin (Sigma), 
and N-acetyl-L-cysteine (Sigma). Antibodies used for immunoblot analysis are listed as follows: 
anti-FLAG (M2, Sigma), anti-p53 (FL393, Santa Cruz Biotechnology), anti-p63 (4A4, Santa Cruz 
Biotechnology), anti-GCLC (HPA036359, Sigma), anti-IDH2 (ab55271, Abcam), anti-RIP 
(610458, BD Biosciences), and anti-β-actin (A1978, Sigma). Cell lysates were resolved by 10% or 
4-12% NuPAGE gels (Invitrogen), transferred onto PVDF membrane (Immobilon-P, Millipore).  
Antibody detection was accomplished using enhanced chemiluminescence method (Western 
Lightning, PerkinElmer) and LAS-3000 Imaging system (FUJIFILM).  
Glutathione assays 
Measurement of intracellular reduced (GSH) and oxidized (GSSG) glutathione concentration was 
performed using the 5,5’-dithio-bis(2-nitrobenzoic acid)-glutathione reductase recycling method 
as previously described35. Briefly, the rate of 5-thio-2-nitrobenzoic acid (TNB) formation was 
determined by measuring the rate of change of absorbance at 412 nm. Linear regressions based 
on values obtained from standard curves were used to calculate concentrations of total and 
oxidized glutathione, which were then used to calculate concentration of reduced glutathione. 
Glutathione concentrations were normalized based on protein concentration determined using the 
BCA Kit (Pierce). Reagents for glutathione assays were obtained from Sigma and include 5-
sulfosalicylic acid dihydrate, DTNB, β-NADPH, glutathione reductase, L-glutathione reduced, L-
glutathione oxidized, triethanolamine, and 2-vinylpyridine. P values for statistical analysis were 
obtained using Student’s t-test. 
Gene expression profiling and heatmap plot 
Total RNA was extracted from cells using TRIZOL (Invitrogen) and was subjected to cleanup 
using the RNeasy Mini Kit (Qiagen) according to the manufacturers’ instructions. RNA samples 
were submitted to the Laboratory for Clinical Genomics at the Washington University in St. Louis 
	   73 
for gene expression microarray analysis using the GeneChip Mouse Gene 1.0 ST array 
(Affymetrix). Heatmap plot was generated using Partek Genomics Suite (Partek).  
 
2.6 Figure Legends 
Fig. 2.1. ∆Np63 abrogates DNA damage-induced oxidative stress and enhances clonogenic 
survival of transformed p53-/-Bax-/-Bak-/- triple-knockout (TKO) mouse embryonic fibroblasts 
(MEFs). (A) ∆Np63 but not a dominant negative mutant of p53 prevents DNA damage-induced 
ROS accumulation. SV40-transformed Bax-/-Bak-/- double-knockout (DKO) MEFs transduced with 
control retrovirus or retrovirus expressing ΔNp63α or dominant negative p53 (p53 DN) were mock 
treated or treated with etoposide (10 µg/ml). Oxidation of the ROS-sensitive dyes H2DCFDA, 
DHE, or MitoSOX Red was quantified by flow cytometric analysis. Data shown are fold increase 
of ROS after etoposide treatment. (B) Cell death was quantified by flow cytometric analysis 
following propidium iodide staining of DKO cells described in (A) at 3 days after etoposide 
treatment. Data are the mean percentage of PI-positive cells ± SD from three independent 
experiments. The expression of N-terminal Flag-HA-tagged ∆Np63 and dominant negative p53 
was assessed by anti-Flag immunoblot (right panel). Asterisk denotes a cross-reactive band 
serving as a loading control. (C) SV40-transformed Bax-/-Bak-/- DKO MEFs transduced with the 
indicated retrovirus were treated with etoposide (10 µg/ml) for 14 hours. Colonies were stained 
with crystal violet after 12 days. The data shown are representative of three independent 
experiments. (D) SV40-transformed p53-/-Bax-/-Bak-/- TKO MEFs transduced with control or 
ΔNp63α-expressing retrovirus were mock treated or treated with etoposide (10 µg/ml). Oxidation 
of the ROS-sensitive dye DHE was quantified by flow cytometric analysis. Data shown are fold 
increase of ROS after etoposide treatment. (E) Cell death was quantified by flow cytometric 
analysis following propidium iodide staining of TKO cells described in (D) at the indicated times 
after etoposide treatment. Data are the mean percentage of PI-positive cells ± SD from three 
independent experiments. (F) c-Myc/Ras or E1A/Ras transformed p53-/-Bax-/-Bak-/- TKO MEFs 
transduced with control retrovirus or retrovirus expressing ΔNp63α were treated with etoposide 
for 9 hours. Colonies were stained with crystal violet after 10 days. *, P<0.05. 
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Fig. 2.2. p63 dictates the homeostasis of intracellular redox through transcriptional controls of 
glutathione metabolism genes. (A) ∆Np63 protects against cell death induced by exogenous 
oxidants. Wild-type MEFs transduced with control or ∆Np63-expressing retrovirus were mock 
treated or treated with diamide (100 µM) for 4 hours or tert-butyl hydroperoxide (TBH, 50 µM) for 
7 hours. Cell death was quantified by propidium iodide (PI) staining. Data are the mean 
percentage of PI-positive cells ± SD from three independent experiments. (B) Schematic 
representation of the effect of ΔNp63α on glutathione metabolism. Overexpression of ΔNp63α in 
cells generates a more reduced intracellular redox state and increases resistance to oxidative 
damage through a coordinated regulation of glutathione metabolism genes. Specifically, ΔNp63α 
upregulates enzymes responsible for (1) glutathione biosynthesis, (2) ROS detoxification by 
glutathione, and (3) regeneration of GSH from GSSG. (C) ∆Np63 upregulates genes involved in 
glutathione metabolism. Bax-/-Bak-/- DKO cells transduced with control or ∆Np63-expressing 
retrovirus were mock treated or treated with etoposide (10 µg/ml) for 6 hours. mRNA levels of the 
indicated genes were analyzed by qRT-PCR and presented as mean ± SD from three 
independent experiments. (D) ∆Np63 generates a more reduced intracellular redox state. Bax-/-
Bak-/- DKO MEFs transduced with control or ∆Np63-expressing retrovirus were mock treated or 
treated with etoposide for 24 hours. Intracellular reduced (GSH) and oxidized (GSSG) glutathione 
concentrations were determined using an enzyme-cycling assay and normalized against protein 
concentration. Normalized [GSH] and [GSSG] were used to calculate the GSH/GSSG ratio. Data 
presented are mean ± SD from at least three independent experiments. (E to H) The ability of 
∆Np63 to prevent DNA damage-induced cell death is compromised by the deficiency of its 
transcriptional targets engaged in glutathione metabolism. Bax-/-Bak-/- DKO cells stably 
expressing GFP or ΔNp63α were transfected with scrambled siRNA (siScr) or siRNA against 
GCLC (E), GSS (F), GPX2 (G), or IDH2 (H). Cells were subsequently mock treated or treated 
with etoposide for 3 days. Cell death was quantified by propidium iodide (PI) staining. Data are 
the mean percentage of PI-positive cells ± SD from three independent experiments. *, P < 0.05. 
Fig. 2.3. Deficiency of ∆Np63α generates a more oxidized intracellular redox state and sensitizes 
cells to oxidative stress. (A) The indicated human cell lines transduced with lentivirus expressing 
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shRNA against GFP or p63 were analyzed by Western blots using antibodies specific for p63 and 
actin. (B) Deficiency of ∆Np63α leads to increased ROS levels. MCF-10A and ME-180 cell lines, 
transduced with lentivirus expressing shRNA against GFP or p63, were stained with CM-
H2DCFDA or H2DCFDA. Oxidation of the respective dyes was quantified by flow cytometric 
analysis. Data shown are fold increase of ROS induced by knockdown of p63 from three 
independent experiments. (C) Deficiency of ΔNp63α downregulates genes involved in glutathione 
metabolism. The indicated human cells lines were transduced with lentivirus expressing shRNA 
against GFP or p63. mRNA levels of the indicated genes were analyzed by qRT-PCR and 
presented as mean ± SD from three independent experiments. (D) Deficiency of ∆Np63α 
generates a more oxidized intracellular redox state. The indicated human cell lines transduced 
with lentivirus expressing shRNA against GFP or p63 were analyzed for intracellular reduced 
(GSH) and oxidized (GSSG) glutathione concentrations using an enzyme-cycling assay. 
Normalized [GSH] and [GSSG] were used to calculate the GSH/GSSG ratio. Data presented are 
mean ± SD from three independent experiments. (E) Deficiency of ∆Np63α sensitizes cells to 
oxidant-induced cell death. The indicated human cell lines transduced with lentivirus expressing 
shRNA against GFP or p63 were mock treated or treated with oxidant diamide in combination 
with antioxidant N-acetyl-L-cysteine (NAC). Cell death was quantified by propidium iodide (PI) 
staining. Data are the mean percentage of PI-positive cells ± SD from three independent 
experiments. *, P < 0.05. 
Fig. 2.4. ΔNp63α mitigates anoikis-induced oxidative stress and cooperates with anti-apoptotic 
BCL-2 to disrupt the luminal clearance of acini in three-dimensional culture of mammary epithelial 
cells. (A) ΔNp63α protects MCF-10A cells from anoikis. MCF-10A cells transduced with retrovirus 
expressing GFP, BCL-2, ΔNp63α, or both BCL-2 and ΔNp63α were grown on poly-HEMA-coated 
plates in the presence of 1% methylcellulose to induce anoikis. Cell death was quantified at the 
indicated times by annexin-V staining. Data are the mean percentage of annexin-V-positive cells 
± SD from three independent experiments. *, P < 0.05. (B) ΔNp63α but not BCL-2 prevents 
anoikis-induced ROS accumulation. MCF-10A cells transduced with control retrovirus or 
retrovirus expressing BCL-2, ΔNp63α, or both BCL-2 and ΔNp63α were grown on poly-HEMA-
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coated plates in the presence of 1% methylcellulose to induce anoikis. Paired samples grown in 
either regular or detachment condition were stained with DHE at 1.5 days. Oxidation of DHE was 
quantified by flow cytometric analysis. Data shown are fold increase of ROS induced by anoikis 
from three independent experiments. *, P < 0.05. (C and D) Coexpression of BCL-2 and ΔNp63α 
disrupts the luminal clearance of acini in three-dimensional culture. MCF-10A cells transduced 
with retrovirus expressing GFP, BCL-2, ΔNp63α, or both BCL-2 and ΔNp63α were cultured in 
reconstituted basement membrane (Matrigel) for 31 days. Acini were fixed and stained for laminin 
5 (red) and nuclear stain 4’,6-diamidino-2-phenylindole (DAPI, blue). Luminal cellularity of acini 
was scored using confocal microscopy.  Clear, 0-25% of the luminal space filled with cell nuclei; 
mostly clear, 25-50%; mostly filled, 50-75%; filled, 75-100%. Representative confocal microscopy 
images from three independent experiments are shown (C). Scale bar indicates 25 µm. Data 
shown in (D) are average of three independent experiments. (E) ΔNp63α prevents intraluminal 
ROS accumulation in three-dimensional acini. MCF-10A cells transduced with retrovirus 
expressing GFP, BCL-2, p63, or both BCL-2 and p63 were cultured in Matrigel for 6-8 days. Acini 
were stained with DHE  (red) and Hoechst 33342 (blue). Representative confocal microscopy 
images are shown. Arrowheads indicate DHE-high cells. Scale bar indicates 25 µm. 
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2.7 Figures 
Figure 2.1 ∆Np63 abrogates DNA damage-induced oxidative stress and enhances 
clonogenic survival of transformed p53-/-Bax-/-Bak-/- mouse embryonic fibroblasts. 
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Figure 2.2 p63 dictates the homeostasis of intracellular redox through transcriptional 
controls of glutathione metabolism genes. 
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Figure 2.3 Deficiency of ∆Np63α  generates a more oxidized intracellular redox state and 
sensitizes cells to oxidative stress. 
 
 
 
	   80 
 Fig. 2.4 ΔNp63α  mitigates anoikis-induced oxidative stress and cooperates with anti-
apoptotic BCL-2 to disrupt the luminal clearance of acini in three-dimensional culture of 
mammary epithelial cells. 
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Fig. S2.1. (A) SV40-transformed Bax-/-Bak-/- DKO MEFs were transfected with scrambled siRNA 
(siScr) or siRNA against RIP1. Cell lysates were analyzed by Western blots using the antibodies 
specific for RIP1 or actin. (B) SV40-transformed Bax-/-Bak-/- DKO MEFs, transfected with 
scrambled siRNA (siScr) or siRNA against RIP1 for 3 days, were treated with etoposide (10 
µg/ml). Cell death was quantified by propidium iodide staining at 3 days after etoposide 
treatment. Data are the mean percentage of PI-positive cells ± SD from three independent 
experiments. 
 
 
 
 
   Data courtesy of Dr. Ho-Chou Tu 
 
Fig. S2.2. p53-/-Bax-/-Bak-/- TKO MEFs are more resistant to DNA damage-induced cell death than 
Bax-/-Bak-/- DKO MEFs. (A) Primary MEFs isolated from two Bax-/-Bak-/- DKO embryos and two 
p53-/-Bax-/-Bak-/- TKO embryos were transformed by E1a and Ras. E1a/Ras-transformed Bax-/-
Bak-/- DKO and p53-/-Bax-/-Bak-/- TKO MEFs were treated with etoposide (10 µg/ml). Cell death 
was quantified by annexin-V staining at the indicated times. Data are the mean percentage of 
annexin-V-positive cells ± SD from three independent experiments. (B) SV40-transformed Bax-/-
Bak-/- DKO or p53-/-Bax-/-Bak-/- TKO MEFs were treated with etoposide (10 µg/ml). Cell death was 
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quantified by propidium iodide staining at the indicated times. Data are the mean percentage of 
PI-positive cells ± SD from three independent experiments.  *, P<0.05. 
 
 
 
 
Fig. S2.3. p53-/-Bax-/-Bak-/- TKO cells were treated with etoposide or etoposide plus N-acetyl-L-
cysteine (NAC, 20 mM) or etoposide plus diphenyleneiodonium (DPI, 100 nM) for the indicated 
times. Cell death was quantified by propidium iodide staining at the indicated times. Data are the 
mean percentage of PI-positive cells ± SD from three independent experiments.  
 
 
 
Fig. S2.4. SV40-transformed p53-/-Bax-/-Bak-/- TKO MEFs transduced with control or ΔNp63α-
expressing retrovirus were mock treated or treated with etoposide (10 µg/ml). Oxidation of the 
ROS-sensitive dye CM-H2DCFDA or MitoSOX Red was quantified by flow cytometric analysis. 
Data shown are fold increase of ROS after etoposide treatment. *, P<0.05. 
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Fig. S2.5. (A) cDNA prepared from Bax-/-Bak-/- DKO MEFs transduced with control or ΔNp63α-
expressing retrovirus was subjected to PCR using primers specific for all isoforms of p63 (Pan), 
TA isoforms of p63 (TA), or ∆N isoforms of p63 (∆N). (B) SV40-transformed Bax-/-Bak-/- DKO 
MEFs transduced with retrovirus expressing shRNA against luciferase or p63, or transfected with 
scrambled siRNA (siScr) or siRNA against p63 were subjected to quantitative RP-PCR analysis 
for p63 expression. Data presented as mean ± SD from three independent experiments. (C) 
SV40-transformed Bax-/-Bak-/- DKO MEFs, tranfected with scrambled siRNA (siScr) or siRNA 
against p63 for 3 days, were mock treated or treated with etoposide (10 µg/ml) for 3 days (left 
panel). DKO MEFs transduced with retrovirus expressing shRNA against luciferase or p63 were 
mock treated or treated with etoposide (10 µg/ml) for 3 days (right panel). Cell death was 
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quantified by propidium iodide staining. Data are the mean percentage of PI-positive cells ± SD 
from three independent experiments. (D) SV40-transformed p53-/-Bax-/-Bak-/- TKO MEFs, 
tranfected with scrambled siRNA (siScr) or siRNA against p63 for 3 days, were mock treated or 
treated with etoposide (10 µg/ml) for 5 days (left panel). TKO MEFs transduced with retrovirus 
expressing shRNA against luciferase or p63 were mock treated or treated with etoposide (10 
µg/ml) for 5 days (right panel). Cell death was quantified by propidium iodide staining. Data are 
the mean percentage of PI-positive cells ± SD from three independent experiments.   
 
 
 
Fig. S2.6. A heatmap representation of glutathione metabolism genes differentially regulated by 
ΔNp63α. DKO cells transduced with retrovirus expressing GFP or GFP-IRES-ΔNp63α were mock 
treated or treated with etoposide (10 µg/ml) for 6 hours. The gene expression profiles were 
assessed using the Affymetrix GeneChip Mouse Gene 1.0 ST array and analyzed for genes 
involved in glutathione metabolism. 
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Fig. S2.7. Immunoblot or qRT-PCR analysis of siRNA-mediated knockdown. (A) Bax-/-Bak-/- DKO 
MEFs transfected with scrambled siRNA (siScr) or siRNA against IDH2 were analyzed by 
immunoblots using antibodies specific for IDH2 or actin. (B to D) Bax-/-Bak-/- DKO MEFs 
transfected with scrambled siRNA (siScr) or siRNA against GCLC, GSS, or GPX2 were analyzed 
by qRT-PCR using the indicated gene-specific primers. Data presented as mean ± SD from three 
independent experiments. *, P<0.05. 
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Fig. S2.8. (A) ME-180 cells transfected with scrambled siRNA (siScr) or siRNA against p63 for 3 
days were subjected to analysis for ROS production or immunoblots using antibodies specific for 
p63 or actin. Oxidation of the ROS-sensitive dye H2DCFDA was quantified by flow cytometric 
analysis. (B) ME-180 cells were transduced with lentivirus expressing doxycycline-inducible 
miR30-based shRNA against p63. Cells were mock-treated or treated with doxycycline (2 µg/ml) 
for three days and analyzed for ROS production and immunoblots using antibodies specific for 
p63 or actin. Oxidation of the ROS-sensitive dye H2DCFDA was quantified by flow cytometric 
analysis. *, P<0.05. 
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Fig. S2.9. (A) MCF-10A cells transduced with lentivirus expressing shRNA against GFP or p63 
for 48 hours were mock treated or treated with doxorubicin (1 µg/ml) for 27 hours. Cell death was 
quantified by propidium iodide (PI) staining. Data are the mean percentage of PI-positive cells ± 
SD from three independent experiments. (B) ME-180 cells transduced with lentivirus expressing 
shRNA against GFP or p63 for 48 hours were mock treated or treated with cisplatin (10 µM) for 
32 hours. Cell death was quantified by propidium iodide (PI) staining. Data are the mean 
percentage of PI-positive cells ± SD from three independent experiments. *, P<0.05. 
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Fig. S2.10. Upregulation of GCLC by ΔNp63α is Nrf2-independent. (A and B) Bax-/-Bak-/- DKO 
MEFs transduced with retrovirus expressing GFP or GFP-IRES-ΔNp63α were transfected with 
scrambled siRNA (siScr) or siRNA against Nrf2. mRNA levels of Nrf2 and GCLC were analyzed 
by qRT-PCR and presented as mean ± SD from three independent experiments (A). Cell lysates 
were analyzed by Western blots using antibodies specific for GCLC or actin (B). (C) Cells 
described above were mock treated or treated with etoposide (10 µg/ml) for 3 days. Cell death 
was quantified by propidium iodide staining. Data are the mean percentage of PI-positive cells ± 
SD from three independent experiments. *, P < 0.05. 
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-CHAPTER THREE- 
 
DNA Damage Induces Mitochondrial ROS Production to 
Execute Programmed Necrotic Death  
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3.1 Introduction 
 Reactive oxygn species (ROS) are potentially harmful reactive derivatives of molecular 
oxygen that can damage all intracellular constituents1. Although they are proposed to be central 
initiators and effectors of programmed necrosis under diverse settings2, much about their 
regulation in this setting remain unknown. Mitochondria are the primary sources of ROS in most 
cell types and are proposed to be major sources of ROS production during programmed 
necrosis2. ROS production occurs during normal physiological processes such as fatty acid 
catabolism and aerobic respiration, and are countered by cellular antioxidant defences3. 
Excessive production and/or impaired antioxidant capacity generates a deleterious state of 
oxidative stress, which can lead to cellular dysfunction and demise1. Intracellular ROS is primarily 
produced by the mitochondrial electron transport chain (ETC) as the unavoidable byproduct of 
aerobic respiration3. The leakage of electrons passing through the ETC leads to the one-electron 
reduction of O2 to O2•— (superoxide), which can then give rise to other ROS such as the hydroxyl 
radical3. 
Depending on the nature of the initial death signal, broadly similar models have emerged 
to explain the mechanism underlying increased mitochondrial ROS production during 
programmed necrosis, with the commonality being that increased electron flow into the ETC is 
proposed to cause increased rate of electron leakage, and hence excessive ROS production2. 
With death receptor ligation-induced RIP1 kinase-dependent “necroptosis”, this can be caused by 
increased entry of energy substrates into the tricarboxylic acid (TCA) cycle due to upregulation of 
glycolysis and glutamine metabolism, itself due to phosphorylation-mediated stimulation of 
metabolic enzymes by the RIP1 interacting partner RIP3 kinase4. TNF receptor ligation can also 
induce superoxide production by the NAPDH oxidase Nox1 to execute necrosis5. In the case of 
ischemia-reperfusion injury, ATP depletion during ischemia impairs the ability of ATP-dependent 
calcium pumps to extrude calcium from the cytosol into the endoplasmic reticulum (ER) or the 
extracellular space6. Increased cytosolic [Ca2+] leads to elevated mitochondrial matrix [Ca2+], 
which stimulates TCA cycle enzymes and thus electron entry into the ETC6. This acute increase 
in mitochondrial oxidative metabolism leads to a burst of ROS generation following reperfusion6. 
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We have reported that DNA double strand break (DSB)-induced programmed necrotic 
death (PND) requires de novo gene expression and is executed by the p53-mediated induction of 
the lysosomal protease cathepsin Q in cooperation with p53-independent induction of reactive 
oxygen species (ROS)7. DNA DSB-induced PND in Bax-/-Bak-/- double knockout (DKO) mouse 
embryonic fibroblasts (MEFs) does not rely on RIP17, thus making it unlikley for RIP3-mediated 
metabolic upregulation to be responsible for ROS production since RIP3 is phosphorylated and 
activated by RIP1 in the necrosome. Genotoxic stress induced by DNA alkylation has previously 
been shown to deplete cellular ATP due to overactivation of the DNA repair enzyme PARP18. 
However, we found that PND induced by DSBs is not dependent on PARP17. Furthermore, in our 
setting, DNA damage-induced ROS production and death requires de novo gene expression7, an 
ATP-dependent process. Additionally, this form of programmed necrosis is also independent of 
cyclophilin D, a primary mediator of calcium-induced necrosis9-11. Thus, it is unlikely for increased 
ROS production to be secondary to ATP depletion and calcium dysregulation, as in the case of 
ischemia-reperfusion injury. Although it is clear that there is a regulated production of ROS in this 
setting, the underlying mechanism(s) are unknown and will be the focus of this chapter. 
 
3.2 Results 
 Though it is unlikely for ATP depletion and subsequent calcium dysregulation to be 
responsible for double strand break-induced ROS production, we nevertheless sought to rule out 
this possible by comparing the kinetics of mitochondrial ROS production and cell death with 
changes in cellular ATP levels. Following treatment of transformed Bax and Bak DKO MEFs with 
the topoisomerase II inhibitor etoposide, which generates DNA double strand breaks, an early 
and sustained rise in mitochondrial matrix superoxide levels was detected by the matrix-localized  
superoxide-specific indicator dye MitoSOX Red (Fig. 3.1A) prior to any detectable cell death (Fig. 
3.1B). Surprisingly, there was a burst of ATP production at 12 hours following etoposide 
treatment, coinciding with the time frame during which superoxide started to increase (Fig. 3.1C). 
Subsequently, ATP levels continued to decline following ROS induction (Fig. 3.1C). These data 
indicate that mitochondrial ROS production is not caused by bioenergetic collapse, as in the case 
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of ischemia-reperfusion injury. Rather, the early increase in ATP levels suggest that double 
strand breaks may induce an early upregulation of ETC activity, leading to ATP and superoxide 
generation. The latter then cooperates with cathepsin Q, with deleterious and eventually lethal 
consequences for the cell. 
The ETC is located in the mitochondrial inner membrane and generates the 
electrochemical gradient required for ATP generation12. Electrons enter the ETC via complex I or 
II and are carried from both by ubiquinone to complex III, then transferred via cytochrome c to 
complex IV, where they leave via the reduction of molecular oxygen to water12 (Fig. 3.2A). Of 
these, complex I and III are accepted as the major sources of electron leakage and hence 
mitochondrial superoxide production, with a minor contribution by complex II implicated in specific 
settings3. To determine whether or not the ETC plays a role in DNA damage-induced ROS 
production, we assayed for the intrinsic enzymatic activity of the ETC complexes I, II, III, and IV in 
isolated mitochondria. Indeed, treatment with etoposide increased the enzymatic activity of 
complexes III and IV, but not of the others. Notably, etoposide did not affect the activity of the 
mitochondrial matrix enzyme citrate synthase (Fig. 3.2, B to F). Since complex IV is not a site of 
superoxide formation, this suggests DNA damage increases mitochondrial ROS production via 
induction of ETC complex III. 
Complex III of the ETC is composed of 11 subunits12. The mechanism of superoxide 
production at complex III is as follows13: 1) complexes I and II transfer two electrons to the mobile 
electron carrier ubiquinone, forming the reduced ubiquinol; 2) the Rieske iron-sulfur protein 
(RISP) subunit of complex III, encoded by the gene Uqcrfs1, sequentially transfers one electron 
at a time from ubiquinol to cytochrome c; 3) sequential single electron oxidation of ubiquinol 
transiently creates the free radical ubisemiquinone, which can then either donate its remaining 
electron to other complex III electron carriers, or donate directly to oxygen to generate 
superoxide. RNAi-mediated knockdown of the RISP subunit prevents ubisemiquinone formation, 
thus abolishing complex III ROS production13-15. Therefore, to test the role of complex III in DNA 
damage-induced ROS and cell death, we used RNAi to knockdown the RISP. We found that 
knockdown of RISP was able to prevent both ROS induction (Fig. 3.2G) and cell death (Fig. 3.2H) 
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following treatment with etoposide. In contrast, knockdown of the essential ETC complex I 
chaperon protein Ndufaf1, loss of which decreases complex I abundance and activity16 and 
inhibits antigen receptor-induced ROS production in T lymphocytes17, did not protect against 
etoposide-induced ROS (Fig. 3.2H) and cell death (Fig. 3.2H), in line with our observation that 
etoposide did not alter complex I activity. 
We next sought to determine whether the canonical ATM-mediated DNA damage 
response to double strand breaks is involved in the induction of ETC complex III activity and ROS 
by etoposide. ATM is a phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) whose activity 
can be inhibited using the compound LY294002. This compound also inhibits PI3Ks as well as 
ATR and DNA-PK, two other PIKKs involved in the DNA damage checkpoint. Though both ATR 
and DNA-PK have been implicated in the response to double strand breaks, ATM is widely 
considered to be the primary mediator18-20. Importantly, we demonstrated that LY294002 blocked 
etoposide-induced ROS as measured by the broad-spectrum ROS indicator H2DCFDA, the non-
mitochondria-specific superoxide indicator dihydroethidium (DHE), and MitoSOX Red (Fig. 3.3A); 
and protected against cell death (Fig. 3.3B). Furthermore, RNAi-mediated knockdown of ATM 
using two siRNA oligos targeting distinct regions of ATM mRNA provided modest but significant 
inhibition of etoposide-induced ROS using all three ROS indicator dyes (Fig. 3.3C), and also 
protected against death (Fig. 3.3D). Knockdown of ATM was confirmed by qRT-PCR (Fig. 3.3E). 
The difference in protection afforded by knockdown of ATM versus treatment with LY294002 
suggests that ATR and DNA-PK are also involved. Notably, ATM provided much greater 
protection against cell death (Fig. 3.3D) than against ROS induction (Fig. 3.3C). This is most 
likely due to abrogation of ATM-mediated activation of p53, whose transcriptional target cathepsin 
Q cooperates in parallel with ROS to execute programmed necrotic death. 
These results provided clear indication that the canonical double strand break-induced 
DNA damage signaling pathway may be involved in upregulating ETC complex III activity in 
response to etoposide. Indeed, LY294002 was able to completely prevent the induction of ETC 
complex III activity triggered by treatment with etoposide (Fig. 3.3F). Immunoblot analysis of the 
mitochondrial outer membrane protein VDAC1 showed it was present in equal amounts between 
	   98 
all samples of isolated mitochondria used for the complex III activity assay (Fig. 3.3G), indicating 
differences in its activity was not due to differences in purity of the mitochondria preparations. 
 
3.3 Materials and Methods  
siRNA 
siRNA oligos were reverse-transfected using LipofectamineTM RNAiMAX (Invitrogen) to a final 
concentration of 10. The mouse siRNA oligos were purchased from Ambion Silencer Select 
oligos (Applied Biosystems): Ndufaf1 #1, 5’-GACACGGAGUUUAUCCAGAtt (Ambion s88121); 
Ndufaf1 #2, 5’-GGCAGUUUCGUGAAAAAGAtt (Ambion s206245); Uqcrfs1 #1, 5’-
CGACUUCUCUGACUAUCGUtt (Ambion s83717); Uqcrfs1 #2, 5’-
GCAUGAUUUAGAUCGAGUAtt (Ambion s83718); ATM #1, 5’-CAUCUAAUGGUCUAACGUAtt 
(Ambion s62693); ATM #2, 5’-GGCUUUUUCCUACGAUUAUtt (Ambion s62694; Ambion Silencer 
Select Negative Control #1. 
 
Reverse transcription and quantitative PCR 
Total RNA was extracted from cells using TRIZOL (Invitrogen) according to the manufacturer’s 
instruction. Reverse transcription was performed with oligo-dT plus random decamer primers 
(Ambion) using Superscript II (Invitrogen). Quantitative PCR was performed with SYBR green 
master mix (Applied Biosystems) in duplicates using indicated gene specific primers. For TaqMan 
probes, quantitative PCR was performed with TaqMan PCR Master Mix (Applied Biosystems). 
Quantitative PCR was performed on an ABI Prism 7300 sequence detection system (Applied 
Biosystems). Data were analyzed as described previously by normalization against GAPDH that 
was detected using TaqMan probes (Applied Biosystems)7. 
 
Cell culture and viability assays 
SV40-transformed Bax-/-Bak-/- double-knockout (DKO) mouse embryonic fibroblasts (MEFs) were 
previously described 7. Cell death was quantified by propidium iodide (Sigma) staining, followed 
by flow cytometric analysis using either a FACSCalibur (BD Biosciences) or a LSRFortessa (BD 
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Biosciences). Data were analyzed using CellQuest Pro (BD Biosciences) or FACSDiva (BD 
Biosciences). P values for statistical analyses were obtained using Student's t test. 
 
Measurement of ROS 
Production of ROS was monitored by flow cytometric analyses using ROS-sensitive dyes. Cells 
were incubated with 1 µM 2’,7’-dichlorofluorescein diacetate (H2DCFDA, Invitrogen) or 1 µM 
dihydroethidium (DHE, Invitrogen) at 37°C for 30 minutes, or with 2.5 µM MitoSOX Red 
(Invitrogen) at 37°C for 10 minutes. Oxidation of the ROS-sensitive dye was quantified by flow 
cytometric analysis using either a FACSCalibur (BD Biosciences) or a LSRFortessa (BD 
Biosciences). Median fluorescence in the appropriate detection channels was assessed by 
FlowJo (Tree Star). Fold induction of ROS was determined by dividing the median fluorescence 
of experimental samples with that of control samples. P values for statistical analyses were 
obtained using Student’s t-test. 
 
Reagents 
Chemicals used are listed as follows: etoposide, acetyl-CoA, malonate, cytochrome C, DCPIP, 
sodium succinate, DTNB, oxaloacetic acid, rotenone, decylubiquinone, antimycin A, sodium 
borohydride, propidium iodide, LY294002 (all Sigma); NADH (Roche). 
 
Mitochondrial isolation, antibodies, and immunoblot analysis 
Isolation of mitochondria was performed using trituration and differential centrifugation as 
previously described 21, using SHE buffer (250 mM D-sucrose, 10 mM HEPES pH 7.4, 1 mM 
EGTA, 0.5 mM PMSF). For electron transport chain activity assays, disruption of mitochondrial 
membranes was achieved with 3 freeze-thaw cycles followed by sonication; mitochondria were 
aliquoted and stored at -80C until use in assays. For immunoblot analysis, lysate was prepared 
from an aliquot of intact mitochondria taken prior to free-thaw and sonication and was resolved by 
10% NuPAGE gel (Invitrogen) and transferred onto PVDF membrane (Immobilon-P, Millipore). 
Antibody detection was accomplished using enhanced chemiluminescence method (Western 
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Lightning, PerkinElmer) and LAS-3000 Imaging system (FUJIFILM). Anti-VDAC1 antibody 
(Mouse anti-Porin 31HL, Calbiochem) was used for immunblot analysis. 
 
Electron transport chain activity assays 
Spectrophotometric assays for electron transport chain complex I-IV and citrate synthase 
activities using isolated mitochondria have been previously described 22 and are summarized 
below. Complex I: NADH:ubiquinone oxidoreductase activity was determined by incubating 
mitochondria in 25 mM K-phosphate buffer pH 7.5 containing 2.5 mg/mL BSA, 5 mM MgCl2, 0.1 
mM NADH, 0.6 mM KCN, and 130 mM decylubiquinone, and either with or without 10 mM 
rotenone in order to determine Complex I-specific, rotenone-sensitive activity. Oxidoreductase 
activity was calculated from the rate of decrease in absorbance at 340 nm due to NADH 
oxidation. Molar extinction coefficient for NADH = 6290 M-1cm-1. Complex II: Succinate 
dehydrogenase activity was determined by incubating mitochondria in 30 mM K-phosphate buffer 
pH 7.5 containing 20 mM sodium succinate, 3 mM KCN, 50 mM DCPIP, and 130 mM 
decylubiquinone, and either with or without 5 mM malonate in order to determine Complex II-
specific, malonate-sensitive activity. Dehydrogenase activity was calculated from the rate of 
decrease in absorbance at 600 nm due to DCPIP oxidation. Molar extinction coefficient for DCPIP 
= 19100 M-1cm-1. Complex III: Ubiquinol:cytochrome c oxidoreductase activity was determined 
by incubating mitochondria in buffer containing 26.7 mM KH2PO4, 2.58 mM EDTA, 0.516 mM 
KCN, 8.6% DMSO, 92.8 mM decylubiquinol, 0.1% oxidized cytochrome c, pH 7.5, either with or 
without 50 nM antimycin A to determine Complex III-specific, antimycin A-sensitive activity. 
Oxidoreductase activity was calculated from the rate of increase in absorbance at 550 nm due to 
cytochrome c reduction. Molar extinction coefficient for cytochrome c = 18500 M-1cm-1. Complex 
IV: Cytochrome c oxidase activity was determined by incubating mitochondria in 10 mM K-
phosphate buffer pH 7 containing 0.1% reduced cytochrome c, with non-specific activity 
determined by performing the reaction without mitochondria. Oxidase activity was calculated from 
the rate of decrease in absorbance at 550 mm due to cytochrome c oxidation. Molar extinction 
coefficient for cytochrome c = 18500 M-1cm-1. Citrate synthase: Activity was determined by 
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incubating mitochondria in 40.4 mM Tris-Cl buffer pH 8.1 containing 0.06 mM Acetyl-CoA, 0.1 
mM DTNB, 0.048% Triton-X 100, and 0.5 mM oxaloacetic acid. Citrate synthase activity was 
calculated from the rate of increase in absorbance at 412 nm due to formation of 5-thio-2-
nitrobenzoate anion from DTNB, with non-specific formation determined by performing the 
reaction without oxaloacetic acid. Molar extinction coefficient for 5-thio-2-nitrobenzoate anion = 
13600 M-1cm-1. Enzyme activity for all assays were calculated as follows: Activity (nmol / min 
/ mg protein) = ΔAbs/(Molar extinction coefficient x protein concentration x volume sample). 
Mitochondria protein concentration was determined using BCA Kit (Pierce). 
 
ATP assay 
Cellular ATP levels were measured by the luciferin/luciferase method using ATP 
Bioluminescence Assay Kit HS II (Roche) per manufacturer’s instructions. Lysates used for ATP 
determination were prepared from 104 cells for each condition, as determined by staining with 
Trypan blue and counting on a hemocytometer. Upon automatic injection of 50 µl of luciferase 
reagents to 50 µl of diluted samples, the luminescence signal was integrated for 10 sec after a 
delay of 1 sec using a Dynex MLX96-well Plate Luminometer (MTX Lab Systems, Inc). Control 
samples were harvested from subconfluent cell populations. 
 
3.4 Discussion 
 We previously reported that DNA double strand breaks activate programmed necrotic 
death via induction of the lysosomal protease cathepsin Q and ROS in a manner dependent on 
de novo gene expression7. Although that study revealed p53 as the transcription factor 
responsible for cathepsin Q upregulation, the mechanism underlying ROS induction was unclear. 
Here, we conclude that the DNA damage signalling pathway mediated by ATM/ATR/DNA-PK is 
responsible for etoposide-induced ROS via increasing the activity of the ETC complex III. The 
mechanism of ETC complex III activity induction will be the focus of future investigation. 
 Given the rapid rise in matrix superoxide (almost two-fold 18 hours following etoposide 
treatment) following etoposide treatment and the dependence of ROS induction on de novo gene 
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expression, the most likely mechanism for ROS induction is the transcriptional upregulation of a 
regulatory protein that alters the activity of existing complex III subunits via protein modification. 
This is more likely than direct transcriptional upregulation of complex III subunits due to the 
kinetics of mitochondrial superoxide induction and the complexity of this enzyme complex. ETC 
complex III consists of 10 subunits encoded by nuclear DNA and 1 subunit encoded by 
mitochondrial DNA12. The mature complex functions as a homodimer and is assembled and 
embedded into the mitochondrial inner membrane in a multi-step process12. Assembly involves 
the formation of three subcomplexes that assemble into a membrane-embedded precomplex, 
which homodimerize with another precomplex before full assembly is completed with the addition 
of the final subunits12. 
 Two likely candidates that may mediate ATM/ATR/DNA-PK-induced upregulation of 
complex III activity are p73 and PGC-1α. p73 is a member of the p53/p63/p73 family of 
transcription factors and is known to mediate cell cycle arrest and apoptosis in response to 
genotoxic stress23. Furthermore, loss of function studies revealed that deficiency of p73 protects 
against DNA damage-induced cell death24. Genotoxic stress can activate p73 via the ATM and 
ATR effector kinases Chk2 and Chk125; and also via the p38 MAP kinase (MAPK) pathway26, 
which can be activated in an ATM/ATR-dependent manner in response to genotoxic stress18. p38 
MAPK can also activate the transcriptional co-activator PGC-1α27, a master regulator of oxidative 
metabolism with an important role in regulating mitochondrial gene expression and biogenesis28. 
Phosphorylation of PGC-1α by the p38 MAPK leads to its stabilization and activation, resulting in 
increased mitochondrial respiration27. PGC-1α can also be activated via phosphorylation by 
AMPK29. Intriguingly, etoposide was recently shown to activate PGC-1α and mitochondrial 
biogenesis via AMPK in an ATM-dependent manner30. Therefore, double strand breaks may 
induce increased ETC complex III activity via activation of PGC-1α. 
The identity of the downstream transcriptional targets that are ultimately responsible for 
regulating ETC complex III activity in response to double strand breaks is unclear due to a lack of 
characterization of complex III post-translational regulation. However, existing data on the better-
characterized ETC complexes I and IV provides some insight into possible regulatory 
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mechanisms. Both complex I and IV have been demonstrated to be regulated via 
phosphorylation31. Phosphorylation of human complex I NDUFS4 subunit at serine 173 promotes 
its mitochondrial matrix import and maturation32 while phosphorylation of bovine complex IV 
catalytic subunit I at tyrosine 304 leads to its inactivation33. Other phosphorylation sites have also 
been identified for complex I and complex IV, though the functional consequences of those are 
unclear. Furthermore, complex I is positively regulated through deacetylation34 and inhibited by S-
nitrosylation of its 75 kDa subunit35, 36. Although proteomics studies suggest complex III also 
undergoes phosphorylation, the residues, effects, and mediators of this are unclear31. However, 
the emerging prominence of post-translational as a mechanism for regulating complex I and IV 
activity suggests complex III is likely to be regulated in a similar manner. Especially provocative is 
our finding that complex IV activity is also upregulated following DNA double strand breaks to a 
similar extent as complex III (Fig. 3.2E), suggesting possible post-translational co-regulation of 
these complexes. 
 Impaired apoptosis is frequently observed in cancers, with evasion of cell death being a 
hallmark of cancer progression37. Recently, cancerous cells have also been proposed to exhibit 
an increased need for antioxidant defences compared to noncancerous cells, likey due to 
metabolic derangements and microenvironmental factors that increase ROS production38. 
Therefore, pharmacological induction of oxidative is currently being evaluated for use as 
chemotherapy38. Our study demonstrates a novel mechanism by which DNA double strand 
breaks can induce increased mitochondrial ROS production in apoptosis incompetent cells. This 
suggests that chemotherapeutic strategies combining genotoxic agents with therapeutics that 
increase mitochondrial oxidative stress may prove particularly beneficial in the clinical setting. 
  
3.5 Figure Legends  
Figure 3.1 Induction of mitochondrial matrix ROS by DNA damage is an early event that 
precedes cell death and ATP depletion 
(A) DNA damage induces early increase of mitochondrial matrix ROS in Bax and Bak DKO 
MEFs. SV40-transformed DKO MEFs were mock treated or treated with etoposide (10 
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µg/ml). At the indicated time points following treatment, oxidation of the mitochondrial 
matrix-targeted ROS-sensitive dye MitoSOX Red was quantified by flow cytometric 
analysis. Data shown are fold increase of ROS after etoposide treatment. Data presented 
are mean ± SD from three independent experiments. 
(B) DNA damage-induced death of DKO MEFs is observed following rise in mitochondrial 
matrix ROS. DKO MEFs were mock treated or treated with etoposide (10 µg/ml) as in (A). 
At the indicated time points following treatment, cell viability was assessed by propidium 
iodide (PI) staining followed by flow cytometric analysis. Data presented are mean 
percentage of PI positive cells ± SD from three independent experiments. 
(C) DNA damage-induced ATP depletion in DKO MEFs occurs later than ROS induction. 
DKO MEFs were mock-treated or treated with etoposide (10 µg/ml) as in (A). At indicated 
time points following treatment, equal numbers of cells were taken from mock-treated or 
etoposide-treated samples for the determination of [ATP]. Data presented are mean ± SD 
from three independent experiments. 
 
Figure 3.2 ETC complex III mediates DNA double strand break-induced ROS and necrosis 
(A) Flow of electrons through the mitochondrial electron transport chain. Electrons enter the 
chain via complex I or compex II; they are transferred to ubiquinol (Q) which carries them 
to complex III; cytochrome c carries electrons from complex III to complex IV, where they 
reduce molecular oxygen to water. 
(B) DKO MEFs were mock-treated or treated with etoposide (10 µg/ml). 40 hours after 
etoposide treatment, mitochondria were isolated and used to determine the activity of 
electron transport chain complex I. Data presented are mean ± SD from three 
independent experiments. 
(C) Mitochondria isolated from MEFs following 40 hours of mock or etoposide (10 µg/ml) 
treatment, as in (B), were used to determine activity of electron transport chain complex 
II. Data presented are mean ± SD from three independent experiments. 
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(D) Mitochondria isolated from MEFs following 40 hours of mock or etoposide (10 µg/ml) 
treatment, as in (B), were used to determine activity of electron transport chain complex 
III. Data presented are mean ± SD from three independent experiments. *, P < 0.05. 
(E) Mitochondria isolated from MEFs following 40 hours of mock or etoposide (10 µg/ml) 
treatment, as in (B), were used to determine activity of electron transport chain complex 
IV. Data presented are mean ± SD from three independent experiments. *, P < 0.05. 
(F) Mitochondria isolated from MEFs following 40 hours of mock or etoposide (10 µg/ml) 
treatment, as in (B), were used to determine activity of citrate synthase. Data presented 
are mean ± SD from three independent experiments. 
(G) Deficiency of complex III but not complex I activity protects DKO MEFs against DNA 
damage-induced ROS. DKO MEFs were transfected with scrambled siRNA (siScr), or 
siRNA against the Ndufaf1 subunit of electron transport chain complex I or against the 
RISP subunit of complex III (encoded by the gene Uqcrfs1). Cells were subsequently 
mock-treated or treated with etoposide (10 µg/ml) for two days before oxidation of the 
ROS-sensitive dye H2DCFDA was quantified by flow cytometric analysis. Data shown are 
fold increase of ROS after etoposide treatment. Data presented are mean ± SD from 
three independent experiments. 
(H) Deficiency of complex III but not complex I activity protects DKO MEFs against DNA 
damage-induced death. DKO MEFs were transfected with scrambled siRNA (siScr), or 
siRNA against the Ndufaf1 subunit of electron transport chain complex I or against the 
RISP subunit of complex III (encoded by the gene Uqcrfs1). Cells were subsequently 
mock-treated or treated with etoposide (10 µg/ml) for three days before cell viability was 
assessed by staining with PI followed by flow cytometric analysis. Data are presented as 
mean percentage of PI-positive cells ± SD from three independent experiments. 
  
Figure 3.3 DNA damage response pathway induces ROS, necrotic death, and ETC complex 
III activity 
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(A) Inhibition of ATM/ATR/DNA-PK-mediated DNA damage signaling protects against DNA 
damage-induced ROS. DKO MEFs were treated with LY294002 (50 mM), etoposide (10 
mg/mL), or both. Conditions using LY294002 were pre-treated with the drug for 30 
minutes before mock or etoposide treatment. Two days after drug treatment, oxidation of 
the redox-sensitive dyes H2DCFDA, dihydroethidium (DHE), and MitoSOX Red were 
quantified by flow cytometric analysis. Data shown are fold increase of ROS after 
etoposide treatment. Data presented are mean ± SD from three independent 
experiments. 
(B) Inhibition of ATM/ATR/DNA-PK-mediated DNA damage signaling protects against DNA 
damage-induced death. DKO MEFs were treated as in (A). Three days after drug 
treatment, cell viability was assessed using PI staining followed by flow cytometric 
analysis. Data presented are mean percentage of PI positive cells ± SD from three 
independent experiments. 
(C) Loss of ATM protects DKO MEFs against DNA damage-induced ROS. DKO MEFs were 
transfected with scrambled siRNA (siScr) or siRNA against ATM. Cells were 
subsequently mock-treated or treated with etoposide (10 µg/ml) for two days before 
oxidation of the ROS-sensitive dyes H2DCFDA, DHE, and MitoSOX Red were quantified 
by flow cytometric analysis. Data shown are fold increase of ROS after etoposide 
treatment. Data presented are mean ± SD from three independent experiments. *, P < 
0.05. 
(D) Loss of ATM protects DKO MEFs against DNA damage-induced death. DKO MEFs were 
transfected as in (C) and mock-treated or treated with etoposide (10 µg/ml). Three days 
following etoposide treatment, cell viability was assessed using PI staining followed by 
flow cytometric analysis. Data presented are mean percentage of PI positive cells ± SD 
from three independent experiments 
(E) DKO MEFs transfected as in (C) were analyzed for ATM expression by qRT-PCR. 
(F) Inhibition of ATM/ATR/DNA-PK-mediated DNA damage signaling protects DKO MEFs 
against DNA damage-induced upregulation of ETC complex III activity. DKO MEFs were 
	   107 
treated with LY294002 (50 mM), etoposide (10 mg/mL), or both, as in (A). 24 hours after 
etoposide treatment, mitochondria were isolated and used to determine the activity of the 
electron transport chain complex III. Data presented are mean ± SD from three 
independent experiments. *, P < 0.05. 
(G) Protein lysates prepared from mitochondrial samples described in (F) were assessed for 
VDAC1 expression by anti-VDAC1 immunoblot. LY = LY294002. Etop = etoposide. 
	   108 
   3.6 Figures 
	   109 
 
	   110 
 
 
	   111 
Figure 3.3 DNA damage response pathway induces ROS, necrotic death, and ETC complex 
III activity 
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-CHAPTER FOUR- 
 
Conclusions, Discussion, and Future Directions 
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4.1 Conclusions 
 
 Although apoptosis is central to the embryonic development and maintenance of adult 
tissue homeostasis in multicellular organisms, the ability for animals lacking central regulators of 
apoptosis to survive through embryonic development and grow into adulthood, albeit at low 
frequencies, clearly indicates the existence of alternative modalities of cell death. The discovery 
of programmed forms of necrotic death, long dismissed as a passive outcome of exposure to 
unmanageable physico-chemical stresses, represents a significant conceptual advance for the 
field of cell death research. But more than that, the potential implications of this conceptual 
revolution for the management of human injury and disease are huge. Cellular necrosis is an 
important cause of tissue injury, and hence morbidity and mortality, under many pathological 
conditions such as during a heart attack or stroke, and in neurodegenerative diseases. 
Furthermore, the eventual ability to manipulate programmed necrosis pathways will likely open 
broad new avenues for the treatment of cancers that are refractory to current therapeutics due to 
impaired apoptosis. Being a new area of research in a field that has long concentrated its efforts 
on apoptosis, the regulatory mechanisms and life versus death determinants of programmed 
necrosis are just starting to be revealed, and only for a select few death signals. In this thesis, I 
sought to increase our knowledge of how cells make life or death decisions in the context of 
programmed necrosis. 
 In Chapter 2, I demonstrated that the less-oxidized intracellular redox environment 
created by ΔNp63α in apoptosis incompetent p53, Bax, and Bak TKO MEFs not only rescued 
them from DNA damage-induced necrosis in the short term, but also enhanced long-term 
clonogenic survival. I further showed that loss of endogenous ΔNp63α creates a more-oxidized 
redox environment in human cancer cell lines, increasing their sensitivity to oxidant- and 
chemotherapeutic agent-induced death. Finally, in a situation analogous to deficiency of Bax and 
Bak, co-expression of antiapoptotic BCL-2 and ΔNp63α enhanced the long-term survival of 
immortalized human mammary epithelium cells that have lost contact with the extracellular 
matrix. These findings establish a central role for the intracelluar redox status in determining the 
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life-or-death outcome of exposure to intrinsic death signals. They also identified an important new 
function for ΔNp63α. 
 In Chapter 3, I extended our prior study into DNA double strand break-induced 
programmed necrotic death by investigating the molecular basis of reactive oxygen species 
(ROS) induction in this setting. My findings described a novel mechanism for increased ROS 
production, in which double strand breaks upregulate the activity of the electron transport chain 
(ETC) complex III. Importantly, RNAi-mediated knockdown of the complex III RISP subunit, 
essential for its ability to produce superoxide, protects Bax-/-Bak-/- DKO MEFs from double strand 
break-induced ROS and necrosis. My data also suggested that induction of complex III activity, 
ROS, and cell death is mediated by the ATM/ATR/DNA-PK DNA damage signalling pathway. 
 
4.2 Discussion and Future Directions 
 
A potential role for ΔNp63α  in the redox regulation of stem cells 
I demonstrated in Chapter 2 that by coordinately upregulating glutathione production and 
utilization, ΔNp63α increases cellular resistance to oxidative stress and cooperates with apoptotic 
inhibition to promote long-term survival. Recent studies in stem cells highlight the need for long-
lived cells to effectively maintain redox homeostasis1. Stem cells in adult mammals can undergo 
both self-renewal and differentiation, enabling them to replace mature cells lost to injury, damage, 
disease, or normal cellular turnover. Since stem cells must remain capable of both regenerating 
themselves and replacing lost progeny throughout an organism’s life, they have been proposed to 
require increased resistance to the long-term effects of ROS and oxidative stress1. Furthermore, 
physiological levels of ROS can also function as second messengers that drive proliferation and 
differentiation2. Therefore, elevated ROS levels may compromise stem cell maintenance by 
inducing excessive cell cycle entry, resulting in premature exhaustion of the stem cell population3. 
In support of this, hematopoietic stem cells (HSCs) from Atm and FoxO knockout mice have 
increased levels of ROS and decreased reconstitution capacity compared to wild-type, defects 
that could be rescued with the antioxidant NAC4, 5. Furthermore, a population of ROS-low HSCs 
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has been identified that has increased reconstitution capacity compared to ROS-high 
counterparts6. Stem cells of the normal mammary epithelium and of the central nervous system 
also have lower ROS levels than their more mature progeny. ΔNp63α is highly expressed in the 
basal layer of the stratified epithelium, where epidermal stem cells required for skin development 
and homeostasis are located7. The profound defects in stratified epithelium development in the 
p63-null mouse are due to impaired stem cell function7. Debate remains over whether this defect 
is due to decreased stem cell proliferative capacity or to impaired differentiation8, 9. In either case, 
my data on ΔNp63α-mediated redox control highlight a potentially critical mechanism used by 
epithelial stem cells to maintain proper function. 
 
Importance of redox control for tumorigenesis and cancer cell survival 
My findings in Chapter 2 also open new avenues for exploring the role of ΔNp63α in 
cancer biology and may lead to new treatment strategies. Similar to stem cells, there is evidence 
that cancer cells also have an increased need for antioxidants compared to normal tissue, likely 
due to metabolic derangements that increase ROS production10,11. The importance of 
antioxidants for tumorigenesis is highlighted by a recent report demonstrating that endogenous 
oncogenic alleles of Kras, Braf, and c-Myc increase baseline activity of the transcription factor 
Nrf2, a master regulator of the antioxidant response12. The same study also showed that 
tumorigenesis in mouse models of pancreatic and lung cancer was impaired by genetic deletion 
of Nrf2 and that antioxidant genes are increased in human pancreatic cancer12. This altered redox 
status of cancer cells presents a potential way of achieving therapeutic selectivity in cancer 
therapy, through inducing ROS generation and/or impairing its elimination13. In support of this 
strategy, a recently identified small molecule inhibitor of the stress response to ROS killed cancer 
cell lines in vitro, caused regression of tumor xenografts in mice, and displayed anti-tumor effects 
in a transgenic mouse model of spontaneous breast cancer, all while having minimal effects on 
non-cancerous cells14. Analogous to normal tissue stem cells, redox control may also be 
particularly important for cancer stem cells (CSCs), a subpopulation of cancerous cells with stem 
cell properties proposed to play a major role in relapse and metastasis11. Breast tumor CSCs 
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were found to have lower ROS levels than cancer cells from a non-tumorigenic population and 
have increased clonogenic survival following exposure to ionizing irradiation (IR)15. Furthermore, 
pharmacological depletion of glutathione resulted in sensitization to IR15. ΔNp63α is 
overexpressed in many types of solid tissue tumors and has been reported to function as an 
oncogene16, 17. Cancers in which it is overexpressed tend to be less-differentiated and more 
aggressive, with increased resistance to treatment and worse progenosis16. Notably, ΔNp63α is 
strongly expressed in the putative adult breast stem cell compartment and also in basal-like 
breast cancer, a clinically-aggressive, poorly-differentiated subtype with stem cell-like features7, 
16. These findings combined with my data points to an important role for ΔNp63α -mediated redox 
control in the maintenance of CSCs in solid tumors and in their resistance to cancer therapy. 
Furthermore, tumors expressing ΔNp63α may be overly-reliant on elevated antioxidants to 
counteract high baseline levels of ROS, and thus may be uniquely susceptible to chemotherapy 
designed to compromise the antioxidant defences. 
 
ΔNp63α  may mitigate matrix detachment-induced defects in fatty acid β-oxidation 
 In Figure 4 of Chapter 2, I presented evidence that co-expression of ΔNp63α and BCL-2 
successful protected loss of short-term viability and enhanced long-term survival of MCF-10A 
immortalized human mammary epithelial that have lost attachment to the extracellular matrix. The 
role of ΔNp63α in regulating glutathione metabolism plays an important role in mediating this 
effect, as reduction of oxidative stress with exogenous antioxidants has been shown to cooperate 
with BCL-2 overexpression to enhance short-term and long-term survival in this setting18. In that 
study, matrix detachment-induced ROS was suggested to compromise cell survival by inhibiting 
energy-production via impairing fatty acid β-oxidation18. Though their study did not demonstrate 
how ROS inhibits β-oxidation in this setting, this is a reasonable outcome of matrix detachment-
induced oxidative stress18. β-oxidation of long-, medium-, and short-chain fatty acids occur in the 
mitochondria matrix. The process begins with the activation of fatty acids into acyl CoAs at the 
mitochondria outer membrane19. Long-chain acyl CoAs are transported into the mitochondrial 
matrix via the carnitine cycle, which involves conversion to acylcarnitines by CPT1 at the outer 
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membrane, transport through the inner membrane via the bidirectional carnitine:acylcarnitine 
translocase CACT, and conversion back into acyl CoA by CPT2 at the matrix-face of the inner 
membrane19. Once in the matrix, long-chain acyl CoA species are oxidized by inner membrane-
bound enzymes while medium- and short-chain species are oxidized by soluble matrix 
enzymes19. The location of these enzymes in the mitochondrial matrix makes them vulnerable to 
mitochondrial ROS; the inner membrane-bound enzymes and CACT are patricularly vulnerable 
due to their proximity to the ETC located in the inner membrane and to potential disruption due to 
lipid peroxidation-mediated membrane damage. In Chapter 2, I reported that ΔNp63α inhibits 
DNA double strand break-induced ROS, and provided evidence in that chapter and in Chapter 3 
that the source of ROS is the mitochondria. Given these findings, it will be interesting to 
determine whether ΔNp63α is enhancing long-term survival of matrix-detached MCF-10A through 
alleviation of oxidative stress-induced defects in β-oxidation in the mitochondrial matrix. 
 
Mechanism for induction of ETC complex III activity by DNA double strand breaks 
 In Chapter 3, I provided evidence that DNA double strand breaks induce ROS production 
through increasing the intrinsic enzymatic activity of ETC complex III. This may occur through 
either transcriptional or post-transcriptional mechanisms. However, assembly of functional 
complex III homodimers in the mitochondrial inner membranes is a complex, multi-stage 
process20, and is less likely to account for acute changes in total ETC complex III activity 
compared with post-translational regulatory mechanisms. Since we had previously reported that 
double strand break-induced ROS requires de novo gene expression21, the most likely 
mechanism for ROS induction is the transcriptional upregulation of a regulatory protein that alters 
the activity of existing complex III subunits via protein modification. Two potential transcriptional 
regulators downstream of ATM/ATR/DNA-PK in this scenario are the transcription factor p73 and 
the transcriptional co-activator PGC-1α, as discussed in Chapter Three. Though complex I has 
been described to be regulated via phosphorylation22, nitrosylation23, and acetylation24, 
mechanisms for post-translational regulation of complex III have not been adequately 
characterized. A proteomic study has identified several sites on complex III that undergo 
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phosphorylation including the Rieske iron-sulfur protein (RISP) subunit reponsible for complex III 
superoxide production 25. We showed in Chapter 3 that RNAi-mediated knockdown of this subunit 
protected Bax-/-Bak-/- DKO MEFs against DNA double strand break-induced ROS and necrosis. It 
will be very interesting to determine whether this subunit does indeed undergo changes in 
phosphorylation status in the setting of DNA damage-induced programmed necrosis. If so, then 
the follow-up experiments will focus on characterizing the functional significance of this, 
identification of the responsible kinase(s) and/or phosphatase(s), and on determining how these 
are regulated by the DNA damage response pathway, either through p73, PGC-1α, or other 
transcriptional regulators. 
 
4.3 Concluding Remarks 
 Although apoptosis is a complex, highly-regulated process, heroic efforts in the field have 
revealed many of its mysteries. Yet, it is instructive to recall that the term “apoptosis” did not even 
exist until four decades ago. That’s less than two generations of investigators. Indeed, many of 
those whose early work were fundamental in elucidating the pathophysiological roles and 
regulation of apoptosis are still active and, indeed, at the forefront of cell death research. Yet, 
their focus, and the focus of the field, is now turning towards a new paradigm in cell death with 
profound implications for human health and disease: programmed necrosis. Necrosis is a form of 
cell death central to the morbidity and mortality caused by heart attacks and stroke, two of the 
leading causes of death in the developed world, and also by other injuries and diseases such as 
acute pancreatitis and neurodegenerative disorders. It has long been dismissed as a passive 
and, worse, inevitable consequence of exposure to unmanageable physico-chemical stresses 
such as prolonged ischemia. Thus, the demonstration of molecular controls for necrosis, not just 
in vitro but in diverse animal disease models, represents not simply a conceptual revolution but 
also the opening of broad new avenues for therapeutic intervention. I am confident that the 
brilliant, dedicated scientists and their scientific progeny who have done so much to unravel the 
secrets of apoptosis over the past few decades will do the same for necrosis in the decades to 
come, for the benefit of all mankind. 
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